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ABSTRACT 
Chronic exposure to environmental carcinogens may trigger development of 
sporadic breast cancer, a multistep tumorigenesis process involving aggregation of 
genetic and epigenetic alterations, resulting in a serial progression from a non-cancerous 
to precancerous stage and eventually malignant breast cancer.  In this study, I used a 
cellular model that simulates induction and progression of chronic breast cell 
carcinogenesis using concentrations of environmental carcinogens which are achievable 
in blood or plasma.  Process of carcinogenesis was measured by certain detectable 
constitutive and transient end points including acquisition of cancer-associated properties, 
increased ROS prodiction, cell proliferation, DNA damage and activation of Erk-Nox 
pathway which could be targeted by non-cytotoxic dosages of dietary compounds.  
Triclocarban (TCC) is an antimicrobial agent present in personal care products.  
This study was designed to investigate the ability of TCC to act as a co-carcinogen and 
therefore induce premalignant breast cell carcinogenesis and enhance 2-Amino-1-methyl-
6-phenylimidazo(4,5-b)pyridine (PhIP)-induced breast cell carcinogenesis in MCF10A 
cells.  My results showed that repeated treatments with TCC induced cancer-associated 
properties of reduced dependence on growth factors and anchorage-independent growth 
in MCF10A cells.  Concurrently, there was increased ROS production, cell proliferation 
and upregulation of Erk-Nox pathway in response to single as well as long term exposure 
to TCC.  Curcumin, a polyphenolic component extracted from the rhizome, Curcuma 
longa, was able to suppress these transient and constitutive endpoints induced in breast 
cells exposed to TCC.  MCF10A cells were also subjected to either individual or 
combined TCC and PhIP exposure.  Cells co-treated with TCC and PhIP had significantly 
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higher levels of cancer-associated properties, ROS production, cell proliferation and Erk-
Nox pathway activation as compared to cells treated with PhIP alone.  The transient and 
constitutive endpoints induced by co-treatement with TCC and PhIP were significantly 
suppressed by mimosine, a non protein amino acid isolated from Mimosa pudica and 
Ergosterol, a sterol found in cell membranes of fungi.  These results proved that TCC has 
the ability to induce breast cell premalignancy and enhance breast cell carcinogenesis 
induced by PhIP in MCF10A cells.  Furthermore, curcumin, ergosterol and mimosine 
could play promising roles in prevention of sporadic breast cancer.  
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Chapter 1 
 
Background and Overview 
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1.1 Breast cancer 
According to National Cancer Institute and American cancer society, cancer is a term 
used for a group of diseases in which abnormal cells divide without control and are able 
to invade other parts of body through the blood vascular and lymphatic systems [1].  
There are many different types of cancers which can arise in any organ of the body but 
share the common characteristic of uncontrolled growth.  Human breast is a glandular 
structure divided into lobules which secrete milk to be  delivered via ducts to the nipple. 
Fat, connective tissue, and lymphatics constitute the rest of breast.  Cancer of breast is 
broadly divided into two subtypes: those originating from ducts are known as ductal 
carcinomas; those originating from lobules are known as lobular carcinomas.  Breast 
cancer is the most common type of cancer among women worldwide.  Cases of breast 
cancer in developed countries far outnumber those in the developing countries 
(Figure1.1).  Breast cancer is also the most common type of cancer and second leading 
cause of deaths among American women after lung cancer [1].  It is projected by 
American cancer society, that approximately 232,340 cases of invasive breast cancer and 
64,640 new cases of in situ breast cancer would be diagnosed in 2013 [1].  In 2013, it is 
estimated that there would be about 39,620 breast cancer related deaths among women 
[1].  Also, about 2,240 cases of invasive breast cancer are expected to occur among men 
in 2013 which is about 1% of all breast cancer cases and 410 deaths are projected to 
occur in men because of breast cancer this year [1].   
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Worldwide incidence and mortality rates of breast cancer
Breast Cancer 2008 Estimates, World Age
per 100,000 Population, Females, World Regions
Modified from cancer research UK,
info/cancerstats/world/breast-cancer
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-Standardized Incidence and Mortality Rates 
 
 http://www.cancerresearchuk.org/cancer-
-world/  assessed April, 2013  
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1.1.1 Stages of breast cancer 
The various stages of breast cancer are classified as follows (Figure 1.2): 
Stage 0: This stage is also called as carcinoma in situ and is of the following three types: 
a) Paget's disease of the nipple: In this condition abnormal cancerous cells are 
confined to the nipple. 
b) Ductal carcinoma in situ (DCIS): cancer cells are found in the ductular lining of 
the breast tissue and the cells have not invaded the surrounding tissues.  
c) Lobular carcinoma in situ (LCIS): It is the cancer affecting lobules of breast and 
cancerous cells do not invade surrounding tissue. 
Stage I 
Stage I is further subdivided into stages IA and IB. 
In the former sub stage, the tumor size is 2 centimeters or smaller.  The tumor is present 
only in the breast tissue and has not spread outside the breast and has not invaded the 
lymphnodes.  In the second substage tumor clusters ranging from 0.2 millimeters - 2 
millimeters may be found in the adjoining lymph nodes.  
Stage II: Here the tumor size is larger than the previous stage and varies between from 2 
to 5 mm but has not yet spread to other far away locations but maybe found in lymph-
nodes of the adjoining area like the axillary lymph nodes.  
Stage III: Tumor size is larger than stage II and is larger than 5 mm.  Tumor clusters 
measuring 0.2-2mm may be found in the adjoining lymph-nodes or lymph-nodes of collar 
bone.  Tumors regardless of their size that have managed to infiltrate and reach the chest 
wall or that reach breast skin are also categorized as stage III breast cancer.
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 NORMAL BREAST                                              STAGE I BREAST CANCER 
                     
STAGE II  BREAST CANCER                               STAGE III BREAST CANCER 
                                             
                  STAGE IV BREAST CANCER                  
Modified from Mayo Clinic website     http://www.mayoclinic.com/ 
Figure 1.2.  Stages of breast cancer  
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Stage IV: 
It is known as the metastasizing stage of breast carcinoma.  Cancer cells are present in 
surrounding lymph nodes and have also invaded the distant parts of the body, such as the 
lungs, distant lymph nodes, skin, bones, liver, or brain. 
 
1.1.2 Classification of breast cancer: 
Breast cancer is disease entity which encompasses varied subtypes on the basis of 
distinctness of patho-morphological characteristics and clinical outcome.  Newer 
diagnostic tools such as immunohistochemistry, cytogenetics and microarray are 
employed for accurate diagnosis and prognosis [2, 3, 4, 5 , 6].  Complementary DNA 
microarray analysis has been used to classify breast cancer into five major subtypes 
which are as follows: Luminal A, Luminal B, Normal breast like, Her2 and basal like 
breast cancer.  However, newer subtypes have also been recently added [2, 6,] (Table 1).  
This categorization takes into account the two major types of epithelial cells found in 
human mammary gland- luminal epithelial cells and basal epithelial cells, the latter are 
also known as myo-epithelial cells.  These two types of epithelial cells can be 
differentiated immuno-histochemically on the basis of expression of different kinds of 
hormone receptors by these cells.  For example, luminal cells express estrogen receptors 
(ER receptors) or progesterone receptors (PR receptors) and are found to be positive for 
cytokeratins 8/18. On the contrary the basal cells are devoid of estrogen receptor.  The 
latter are however, found to be positive for the expression of cytokeratins 5/6, and 17.  
The basal type of breast cancers are also sometimes called as triple negative breast 
cancers because they are found to lack Human epidermal growth factor receptor 2 (HER2 
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receptors) too.  Nonetheless there are some recognized differences between the basal type 
breast cancers and triple negative breast cancers.  Approximately seventy five percent of 
basal like cancers have been found to be triple negative but the remaining twenty five 
percent of the basal cancers have been found to exhibit either the cell surface receptor 
Her2 or the two hormone receptors.  Around three fourths of the triple negative breast 
cancers are considered as basal like breast cancers [2, 7].  Triple negative character is 
exhibited by the following breast cancer subtypes: basal like cancers, normal breast like 
tumors and breast cancers occurring due to the deficiency or abnormality of BRCA1 
(Breast cancer 1, early onset) gene.  Triple negative cancers are defined as tumors that 
lack ER, PR and HER2 expression.  Moreover, triple negative cancers account for 
approximately ten to twenty-five percent of all the cancers of the breast tissue [8, 9] and 
can show different kinds of histologic patho-morphology.  Triple negative cancers are 
found to occur predominantly in younger women less than fifty years of age and women 
belonging to African American ethnicity. 
 
1.1.3 Risk factors for Breast cancer: 
A risk factor may be defined as any stimulus that increases a person's chance of getting a 
disease. Different risk factors are associated with different types of cancers.  There are 
some known risk factors for breast cancer. According to National Cancer Institute, 2011, 
being born as a female is an overwhelming risk factor for the development of breast 
cancer in women [1].  Many of the other risk factors for breast cancer include the 
following: age at menarche, age at first live birth, and age at menopause.  Age is a 
significant risk factor with the chances of developing breast cancer increase with 
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increasing age in women.  Only about 6% of breast cancers in the United States are 
known to occur in women under the age of forty years.  However, in contrast to the 
women who are more than forty years of age, younger women are often found to be less 
affected with breast cancer which is generally a much more severe disease in younger 
women with a poorer prognosis and which generally progresses to advanced stages.  
Also, these younger women affected with breast cancer have higher rates of breast cancer 
recurrence and breast cancer related mortality [10].  Sixty seven percent of the cases 
categorized as invasive breast cancers occur in women who are fifty five years or are 
older.  Breast cancer seldom occurs in females younger than twenty five years of age, but 
there can be an exception to this fact when breast cancer runs in the family.  Hormonal 
levels influence the development of breast cancer and are important risk factors for the 
development of this disease.  Many factors are known to influence proliferation and 
growth of cells of mammary gland.  The most important among them are estrogen and 
progestins.  Others might include transforming growth factor alpha and epidermal growth 
factor family proteins [11].  Levels of endogenous steroid sex hormones are strong 
determinants of breast tumor development risk.  Infact, female menopausal breast cancer 
patients were found to have higher levels of steroid hormones including androgens and 
estrogens in their circulation [12].  Chances of acquiring mammary gland neoplasia may 
be affected by other hormone- related events.  There is an elevation in the risk of breast 
cancer development for a small time period following delivery of a newborn.  After that 
there is lessening of predisposition to developing mammary neoplasia for an extended 
period of time post-delivery, especially in case of younger females [13, 14, 15].  In one 
study, women who experienced a first full-term pregnancy before the age of twenty 
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years, had their chances of developing breast cancer reduced by half when compared to 
women who never became pregnant.  The former also had significantly lower chances of 
breast cancer development than the females who successfully completed their first 
pregnancy at the age of 35 years or later [16, 17].  Age at which women start their 
menstruation cycles, also affects breast cancer development risk later in their lives.  
Women reaching puberty at an earlier age, for example, if they attained puberty when 
they turned 11 years or an earlier age, were found to be more at risk of developing breast 
cancer by about 20% as compared to women who reached puberty when they turned 14 
years or later [18].  Women reaching menopause at a later age than that is normal for 
most women also have significant chances of developing breast cancer.  Obese 
postmenopausal women have been shown to be more predisposed to develop breast 
cancer [19].  In addition, there are other factors associated with reproduction that may 
also influence breast cancer development.  Ovarian hormones may influence 
development of breast cancer.  Ovariectomy is known to reduce breast cancer risk by 
around three quarters.  This kind of reduction can be greatly influenced by a women’s 
age, her weight, and number of children she bears.  It was seen that ovariectomy was 
most useful in reducing breast cancer development risks in cases of younger women who 
were not overweight and didn’t have any children [20, 21].  The removal of uterus and 
ovaries was also shown to reduce the risk of breast cancer [22].  Individual genetic 
makeup also predisposes women for developing breast cancer.  Moreover, the inheritance 
of defective genes has the capability to enhance the potential of known mutagenic agents 
and factors that are known to promote growth and proliferation of breast tissue ultimately 
leading to tumorigenesis in breast tissue.  About 5%-10 of breast cancers are known to be 
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hereditary in nature and a prior familial history of breast cancer i.e. women with other 
close relatives afflicted with breast cancer like mother, siblings or aunts,  predisposes 
them towards mammary gland neoplasia.  Mutations in the following two genes: BRCA1 
& BRCA2 accounts for the majority cases of hereditary breast cancers [23, 24, 25].  Even 
though women with a familial history of breast cancer are more predisposed to breast 
cancer development, yet only one in five women with relatives affected with breast 
cancer has been shown to carry germ line mutations in BRCA1 and BRCA2 genes [26, 
27].  Mutations affecting BRCA1 are much more common than those affecting the related 
BRCA2 gene [28].  Mutations in the latter gene have been associated with breast cancer 
development in men [29]. 
Most of the women afflicted with Li- fraumeni syndrome are known to suffer from breast 
cancer.  In women suffering from Li- fraumeni syndrome, germ line mutations are found 
in P53, which is an important tumor suppressor gene [30].  Women younger than twenty 
years of age who underwent radiation for treatment of other types of cancers were shown 
to have a high risk of up to 20% to 30% more, for the development of breast cancer as 
late as twenty to thirty- years after radiation therapy [31].  Exposure to ionizing radiation 
enhances the breast cancer development risk [32].  Other surgical and medical procedures 
utilizing radiation as diagnosis or treatment have been linked to higher risks of breast 
cancer development [33].  Moreover, women who are known to be heterozygotes for 
ataxia-telangiectasia gene possess enhanced predisposition to develop malignancies of 
the breast tissue [34].  Race is an important risk factor for the development of breast 
cancer.  White women are more at risk of developing breast cancer as compared to the 
women of African-American, Hispanic, and Asian origin, even though the breast cancers 
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affecting black women have been found to be highly aggressive.  Obesity and being 
overweight are other important factors associated with increased risks of breast tissue 
cancers [35].  Higher levels of leptin hormone secreted by adipose tissue cells, especially, 
those forming breast tissue microenvironment are postulated to influence development of 
breast cancer by aiding in angiogenesis and can also enhance metastasis and mortality 
due to breast cancer in obese women [35].  Obese women are not only predisposed to 
develop breast cancer but are also likely to have a poorer prognosis of the disease [36].  
Obesity also happens to be a risk factor for women for breast cancer recurrence.  Being 
overweight can not only increase the risk of the breast cancer recurrence in women who 
have had the disease, but it also is known to increase the risk of breast cancer 
development among postmenopausal women.  Researchers have tried to shed light on the 
probable link between obese post-menopause state and breast cancer in recent years [19], 
where they have found that systemic and local mammary metabolism which gets 
upregulated in obese subjects, leads to activation of progesterone receptors which in turns 
aids in the development of post-menopausal PR positive breast cancer.  Other factors like 
the use of hormone replacement therapy, alcohol consumption, cigarette smoking and 
sedentary lifestyle with no physical activity, also enhance the risk for development of 
breast cancer which will be discussed in the subsequent sections.  Since less than ten 
percent of breast cancer is of hereditary origin and more that 90% is attributable to non-
genetic factors, therefore, it becomes imperative to study in detail, the role played by 
environment agents in predisposing women to develop breast cancer [37]. 
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1.1.3.1 Environmental Carcinogens: 
Carcinogens are defined as any of the natural or synthetic substances that have the 
potential to cause cancer.  Humans are subjected to an exposure from a wide range of 
chemicals from the environment each day through air, water, soil and food.  Also, 
humans are exposed to hazardous chemicals in their work environment on a day today 
basis.  Even, individual lifestyle factors are important contributors affecting our general 
health and predisposition to diseases like breast cancer [38].  Further as stated above, 
greater than 90% cases of breast cancer are non-hereditary and are classified as sporadic 
breast cancers [37].  In order to formulate an effective strategy for prevention and control 
of sporadic cancers, knowledge of everyday chronic exposures to low doses of 
environmental pollutants is of utmost importance especially for understanding 
pathogenesis of carcinogenesis process which ca then be used to devise preventive 
measures that can intervene with the process of carcinogenesis attributable to 
environmental agents.  The American Cancer Society [1] has put forth a classification of 
some of the environmental factors which possess the potential to cause the non-hereditary 
form of breast (Table 2) cancer which are classified into the following categories 
according to their mode of exposure: carcinogens related to lifestyle (smoking, alcohol, 
diet, sedentary life style), naturally occurring substances (ultraviolet rays, infectious 
agents, radon), chemicals found in the home and workplace, infectious agents, 
carcinogens coming through medical treatments (hormone replacement, immune-
suppressing treatments, exposure to radiation) and others.  
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1.1.3.2 Risk factors related to lifestyle  
Risk factors associated with our lifestyle in general are not the causative or etiological 
factors for breast cancer but act as predisposing factors.  High dosage exposure to 
carcinogens can be associated with a particular occupation or accidental exposure to a 
potentially hazardous material.  Individual behavioral peculiarities such as being under 
any kind of addiction can also expose human body to direct cancer causing agents i.e. 
carcinogens [39, 40].  In the same study it was also noted that among other factors, 
habitual smoking, heavy drinking, unhealthy and imbalanced diet consumption, obesity 
and complete absence of any form of physical activity are prominent contributors for 
cancer in high-income countries [39]. 
 
1.1.3.2.1 Tobacco smoking 
Cigarette smoking is a well-known and significant risk factor for initiation and 
progression of carcinogenesis [41].  Thousands of components found in cigarette smoke 
have been found to be mutagenic since it contains both promoters as well as initiators of 
carcinogenesis process and hence tobacco smoke can be considered as a complete 
carcinogen [40].  Habitual smoking is a major cause of cancer mortality worldwide and 
either directly causes or predisposes humans towards many different types of cancers 
such as those affecting lungs, upper digestive tract, esophagus, stomach, pancreas, liver, 
bladder, kidney, mammary and cervical cancers, bone marrow [English et al 1995.  
Despite the fact that there is no direct evidence of smoke originating from tobacco acting 
as a direct cause of breast cancer, recent reports suggest that components of smoke from 
tobacco, such as NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and 
14 
 
Benzoapyerene, can together play the role of co-carcinogens in sporadic breast cell 
carcinogenesis [42].  Moreover, more recently, evidence has accumulated to link chronic 
habitual smoking and being a smoker from a very young age with risk of breast neoplasia 
[43].  In addition, passive smoking may increase the risk of breast cancer in post-
menopausal women [43]. 
 
1.1.3.2.2 Alcohol consumption 
Role of alcohol as a carcinogen is under constant scrutiny. Habitual drinking can play the 
role a risk factor for carcinogenesis of various organs as was revealed by meta-analysis of 
over two hundred studies [44].  Alcohol has been classified as a human carcinogen.  
Alcohol can promote carcinogenesis by various ways which may include the following: 
induction of enzymes like CYP2E1, an enzyme involved in the metabolism of 
xenobiotics in the body, to generate carcinogens from pro-carcinogens, activation of 
MAPK signaling, cellular oxidative stress, and in breast cells alcohol may cause increase 
response to endogenous estrogens [45].  Moreover, data from several epidemiological 
studies shows that alcohol consumption is indeed associated with increased risk of breast 
cancer occurrence [46].  It has also been shown to act as a potentiator of carcinogenic 
effects of others like tobacco [46].  Some researchers however, consider it only as a 
tumor promotor or a co-carcinogen [47]. 
 
1.1.3.2.3 Diet 
With busier and high tech lifestyles of the present day, quality of diet, especially in 
thedeveloped world,  has deteriorated and has become ever more unhealthy with fast food 
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and fried food forming major chunk of food.  Unbalanced diet which is high in fat, 
protein and carbohydrates and low in fiber is associated with high prevalence of cancers 
especially that affecting colon, prostate, endometrium and breast.  But this can be 
countered by a regular balanced consumption of different kinds of natural antioxidants 
present in a wide array of fruits and vegetables [48, 49].  Diet can also be an unwanted 
source of carcinogens.  Among the various  dietary carcinogens , 2-amino-1-methyl-6-
phenylimidazo [4,5-b]pyridine (PhIP), is one of the most abundant heterocyclic amines, 
found in high-temperature cooked meats or well done meats such as grilled/barbecued 
meats [50, 51, 52].  Consumption of well-done meats containing PhIP has been suggested 
to act as a risk factor for development of breast cancer in some epidemiological studies 
[53]. 
 
1.1.3.2.4 Overweight, obesity and sedentary lifestyle 
Obesity is touted as an important risk factor for cancer.  Some authors have suggested 
that obesity can exacerbate cancer mortality [54].  Rates of breast cancer in western 
world are considerably higher than that found in the developing world.  But, the risk of 
breast cancer in immigrant populations after their settlement in US has steadily risen after 
migration which is mostly attributed to changed life style after migration.  Even breast 
cancer risk in relatively developed Asian countries like Japan and Taiwan, has also 
increased in recent times.  A prospective cohort study suggested that energy imbalance 
with high dietary intake and less consumption by means of physical inactivity may be 
associated with high risk of breast cancer particularly in premenopausal women [55]. 
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1.1.3.3 Naturally occurring substances: 
 
1.1.3.3.1 Ultraviolet rays 
Ionizing radiation and ultraviolet rays have the potential to damage DNA and cause 
cancer. UV irradiation is one of the foremost risk factors for the development of skin 
cancer [56, 57, 58]. Tumors induced in response to UV radiation exposure, have shown a 
sharp rise in the United States, Europe and Australia [59].  Recently, however, exposure 
to UV radiation has been associated with a decreased risk of cancer in children [60] 
. 
1.1.3.3.2 Infectious agents 
The role of viruses first came to the fore when Bitters in 1936, found that a filterable 
agent, after being transmitted via milk caused breast cancer in suckling mice [61], which 
was later identified as a retrovirus. Since then there have been efforts to find whether 
there is a virus that specifically causes human viral mammary tumors but there is not 
concrete evidence of a direct link in this regard [62].  A significant 15% to 20% of 
neoplastic conditions are known to be caused by infectious agents including viruses, 
bacteria and parasites [63].  Some infections can enhance tumorigenicity induced by 
another primary agent wherein they themselves only cause immunosuppression related to 
infection induced inflammation.  Certain infectious agents are known to be causative 
agents of cancer for example, H. pylori ,a bacterium found in stomach, is an important  
risk factor for the subsequent development of  stomach cancer [64] and human papilloma 
virus (HPV) is known to be associated with cervical cancer [65].  Recent research has 
uncovered newer emerging pathogens capable of causing neoplasia in humans [66].  
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Moreover recent studies show that polycyclic aromatic hydrocarbons (PAH) and 
tumorigenic viruses can cause carcinogenic synergy [67].  In the later study it was shown 
that in response to PAH there was ROS-induced DNA damage and, human polyoma virus 
T antigen expressing cells impaired DNA repair, to potentiate overall the carcinogenicity. 
 
1.1.3.3.3 Radon 
Radon, a colorless, odorless, radioactive gas produced due to radioactive decay of 
uranium or thorium, is the second leading cause of lung cancer, after smoking. Radon is 
responsible for about 21,000 lung cancer deaths in US every year [68].  Radon is found in 
soil rock; even it is present indoors, with the maximal levels found to be present in 
basements areas from where it seeps via gaps in floors or walls. Even recent studies have 
found links of levels of radon exposure and lung cancer [69].  Recently, radon related 
lung cancers were found to occur more frequently among smokers [70]. 
 
1.1.3.4 Chemicals in the home and workplace 
As per National Institute of Environmental Health Sciences description, chemical 
carcinogens are substances and circumstances that either are "known" or are "reasonably 
anticipated" to produce cancer.  There is a long list of chemicals that are considered as 
carcinogens.  Certain pollutants of the environment are thought to behave like hormones 
for example organo-chlorine pesticides can exhibit estrogen like activity and therefore 
might induce or influence development of breast cancer [71 ].  Chemicals such as 
benzene, auto exhaust, cigarettes, industrial processes and some consumer goods, have 
been associated with development of cancers while many others are being researched for 
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possessing potential carcinogenic activity.  Some important carcinogenic chemicals are 
listed as under: 
 
1.1.3.4.1 Diesel exhaust: This is produced by diesel motor driven vehicles used at 
construction sites or those used on roads and on farms.  It not only causes environment 
pollution but also has been linked to the risk of lung cancer development [72, 73].  
Inhalation of passive smoke from the surrounding environment, which was found to 
contain several thousand chemicals, out of which greater than sixty have been associated 
with the risk of developing cancer including lung cancer [74, 75, 76].  Asbestos is another 
chemical, exposure to which predisposes people to developing several diseases of lungs 
including cancer, mesothelioma, laryngeal cancer and gastrointestinal cancers and over 
200, 000 deaths were expected to occur in 2010 due to asbestos induced cancers of the 
lung and mesothelium.  The total deaths in US due to asbestos-related lung cancer, 
mesothelioma and asbestosis from workplace exposure resulted is estimated to be over 
200,000 for year 2010 [77, 78].  Recent studies have shown people working in ship 
breaking business are predisposed to several types of cancers including oral and 
nasopharyngeal tumors, lung cancer and liver cancers because of possible exposure to 
asbestos and other metals [79]. 
 
1.1.3.5 Medical treatments (hormone replacement, immune-suppressing treatments) 
To treat postmenopausal discomfitures, hormone replacement therapy (HRT) is widely 
used in women. It has also been used for treatment of osteoporosis and ailments of 
cardiovascular impaired cognitive functions and dementia in menopausal women. 
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However, several studies have raised concerns over its purported effectiveness in such 
treatments [80, 81].  Some studies report that use of hormones can increase the risk of 
breast cancer [82].  This type of therapy can increase the risk of other types of cancers 
like ovarian, colorectal and brain cancers [83, 84, 85].  In case of organ or graft transplant 
patients, immunosuppressive drugs are administered to reduce the chances of graft 
rejection. But since these agents are known to lower the immunity in the patients, such 
patients are highly at risk to contact infections and even cancers, [86, 87].  Since extreme 
immunosuppression has been suspected to be related to certain drugs used for treating 
cancers of skin and lymphoma [81, 88], these drugs should be used with extreme care and 
caution.  
 
1.1.3.6 Others  
Silica, nickel and cobalt have been related to cancer causation [89].  Moreover, some 
other chemicals used in day to day life have been suspected to play important role in 
carcinogenesis process which includes among others the following: antiperspirants, 
talcum powder, hair dyes, and cosmetics [90].  However, some researchers suggest that a 
pronounced carcinogenic effect only is reflected if the exposure occurs at an occupational 
level [91].  In addition, there are other well known carcinogens like 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene (B[a] P) that 
can affect breast cancer development [42].   
In this discussion of carcinogens so far, I have reviewed only some of the chemicals 
known to be carcinogenic.  Moreover, apart from the chemicals that are known 
carcinogens, there are many other chemicals whose carcinogenic potential is unknown.  
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In this study, I use two chemicals to which human bodies are exposed continuously on an 
everyday basis: Triclocarban (TCC), or 3, 4, 4’-trichlorocarbanilide, an antimicrobial 
agent and the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine or 
PhIP. 
 
1.1.3.7 Triclocarban 
Triclocarban (TCC), or 3,4,4'-trichlorocarbanilide (Figure 1.3), is an antibacterial agent 
commonly used in personal care products such as disinfectants, soaps, body washes 
deodorants, detergents, cleansing lotions, wipes etc [92].  Antibacterial activity is 
attributed to its ability to disrupt cellular membranes [93] by inhibition of the enzyme 
enoyl-acyl carrier protein reductase (ENR) which is only present in some bacteria and 
fungi.  The enzyme prevents the synthesis of fatty acids needed for building cell 
membranes and other vital functions.  Many researchers have detected the presence of 
TCC in surface waters and sewage sludge [94, 95, 96, 97, 98].  These studies therefore 
suggest that the widespread use of personal care products containing TCC may pose risks 
for human health.  But, adverse effects of trichlocarban on humans are largely unknown. 
A study involving rats [99], revealed that continuous incorporation of TCC in a diet at 
3,000 or 10,000 ppm for six months lead to degenerative changes in seminiferous tubules 
and oligospermia.  However, testicles didn’t develop any pathological changes in rats fed 
TCC at 1000 ppm. In a study conducted in 1979 [100], a group of rats was fed various 
levels of a diet containing TCC and 3-trifluoromethyl-4, 4’- dichlorocarbanilide in the 
ratio of 2:1.  
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Figure 1.3 Chemical structures of carcinogens  
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  The cohort that was fed the diet comprising of mixture at 0.25% was found to exhibit a 
reduction in the conception rate, number of live births and survival rate among those that 
were born. Recent research has shown that TCC can act as an endocrine disrupter. It has 
been shown to augment the activities of certain steroid hormones [101].  In recent in vitro 
studies, which used reporter gene assays, it has been reported that although TCC did not 
possess any agonist activity for estrogen receptor or androgen receptor in recombinant 
estrogen or androgen responsive cells, yet in the presence of estrogen and testosterone, 
TCC was found to amplify their hormonal actions. Another study by Chen et al [102], 
reported that in the presence of testosterone hormone, TCC was found to enhance 
testosterone’s hormonal effects.  However, TCC failed to affect protein expression of 
androgen receptor or AR mediated signaling.  Also, TCC didn’t interfere with 
testosterone for its binding to androgen receptor.  Simultaneous administration of 
testosterone and TCC in diet to castrated male rats at 0.25% for 10 days lead to a 
significant increase in weight of accessory sex organs in comparison to rats that were 
exposed to either testosterone or TCC alone.  TCC was shown to increase embryo 
production in freshwater mud snails, in a way, mimicked an exposure to certain 
environmental estrogens [103].  Researchers [104] have shown that TCC at nanomolar 
concentrations predisposes rat thymocytes to oxidative stress.  The Material Safety Data 
Sheet (MSDS) for TCC states that TCC is a hazardous chemical that may cause cancer 
and damage to the genetic material [105] due to the possible presence of p-chloroaniline, 
a Proposition 65 carcinogen.  TCC was shown to strongly augment the overexpression of 
aromatase AroB, which is a known target gene for estrogen, in response to treatment with 
exogenous estrogen in zebrafish brains.  TCC exposure alone could however, stimulate 
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AroB expression only slightly [106].  Even though TCC has been postulated to act as an 
endocrine receptor, recently, [107] it was shown that TCC mediated activation of 
xenobiotic metabolism.  Authors in this study [107] used a luciferase based reporter 
assay, to demonstrate that TCC activated nuclear xenobiotic receptors: ER-alpha and 
constitutive active/androstane receptor (CAR).  In the same study, it was also shown that 
TCC activated ER-alpha in female rat ovaries leading to induction of Cyp1b1 and also 
induced promoter activity of estrogen receptors.  Moreover, TCC treatment in mice also 
resulted in induction of CAR target gene: UGT1A and Cyp2b10.  
Direct dermal exposure to TCC results in transdermal absorption and accumulation in 
underlying tissues, including mammary tissues [108.].  A single whole-body shower 
using TCC-containing soap results in blood levels as high as ~500 nmol/L within 3 h 
[109, 110].  In addition, TCC is resistant to both wastewater chemical and biological 
treatments, and agricultural use of TCC-containing bio solids renders TCC into the food 
chain, thus increasing human exposure to TCC [101, 111, 112, 113, 114].  Although the 
role of TCC in increasing breast cancer risk has been questioned, it has not yet been 
addressed.  It is imperative to clarify the role of low-dose TCC in sporadic breast cancer 
development and to identify effective agents for intervention and this precisely is the 
objective of this study.  
  
1.1.3.8 PhIP 
2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) (Figure 1.3) is heterocyclic 
amine (HCAs) abundantly found in high temperature cooked meats particularly produced 
during grilling and barbequeing procedures [115, 116, 117].  Consumption PhIP via such 
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meats has been associated with an enhanced risk of breast neoplasia by epidemiological 
studies [118, 119].  People who took PhIP at microgram level concentrations via 
ingestion, had PhIP available systemically at picomolar and nanomolar concentrations 
[117].  Gastric administration of milligram levels of PhIP induced tumors of mammary 
gland [117].  Several studies have reported that PhIP is genotoxic to human cells and a 
concentration of PhIP as low as 450 nmol/L induced DNA adduct formation [117, 118, 
119, 129].  Recently, it was reported that long-term exposure of breast cells to PhIP at 
physiologically-achievable, picomolar to low nanomolar doses induced carcinogenesis 
and tumorigenicity [121].   
 In one study, rats were fed PhIP at the rate of 75mg/Kg for 10 continuous days 
and this treatment induced proliferation of ductular epithelium, formation of carcinoma in 
situ and also mammary gland neoplasia in which high occurrence of H Ras gene 
mutations were found [122].  Induction of expression of oncogenic H-Ras in breast 
epithelial MCF10A cells confers to MCF 10A cells the capability of invasion which was 
accompanied by enhanced expression of metalloproteinases (MMP-2 and MMP- 9) [123] 
and ERK (extracellular signal-regulated kinase) pathway activation [124].  Activation of 
the ERK pathway causes increased expression of NADPH oxidase-1 (Nox1) and the 
enzyme Nox-1 in turn mediates generation of reactive oxygen species (ROS), which 
causes increase in cell proliferation, cellular motility, enhanced power of invasion, and 
neovascularization [124, 125].  Transient exposure of MCF 10A cells at nanomolar doses 
of PhIP caused increased cellular proliferation and activated the ERK pathway [126].  
During this activation of ERK pathway, a cascade ensues wherein activation of 
downstream members of the ERK pathway members like Raf, Mek, and Erk which 
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ultimately generated signals for cell proliferation, cell survival and cellular differentiation 
and constitutively activated ERK pathway predisposes cells to malignant transformation 
[127].  Repeated exposures to physiologically achievable levels of PhIP in the range of 
picomolar to nanomolar concentrations effectively induced progressive carcinogenesis of 
human breast epithelial MCF10A cells from a non-cancerous stage to premalignant and 
malignant stages in a concentration and exposure dependent way [121].  Step wise 
induction of carcinogenesis was accompanied by acquisition of cancer-associated 
properties of reduced dependence on growth factors, anchorage-independent growth, 
acinar-conformational disruption, increased cellular proliferation, migration, invasion and 
carcinogenesis in mouse models. In addition an upregulated H-Ras gene expression, ERK 
pathway activation with downstream elevation of Nox-1 expression, and elevated 
reactive oxygen species production was noted [121].  Epicatechin gallate and 
epigallocatechin gallate, the green tea catechins, were found to suppress PhIP stimulated 
cellular carcinogenesis and mammary gland neoplasia [121]. Dipyridamole (DPM), at a 
non-cytotoxic physiologically achievable dose of 10nmol/L, effectively blocked breast 
cell carcinogenesis induced by cumulative exposures to three different carcinogens 
including PhIP [128].  DPM could block H-Ras upregulation, and downstream ERK 
pathway activation, reactive oxygen species (ROS) generation, and DNA damage 
induced by transient and chronic exposures to PhIP [128].  PhIP at sub nano molar 
concentrations has been shown to possess estrogenic activity and was shown to promote 
metastatic potential in mammary cancer cell lines and T47D and MCF 7 cells, as seen by 
the enhanced ability of the cells to digest and migrate through reconstituted basement 
membrane model [129]. 
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1.2 Precancerous Model of Cancer Progression 
Since breast cancer is an important cause of deaths among women especially in the 
developed world and more than 85% of breast cancers are sporadic in nature attributable 
to long-term exposure to small quantities of environmental carcinogenic agents that 
progressively induce non-cancerous cells of breast to acquire pre-malignancy and 
gradually to malignancy in a multi-year, multi-step, and multi-path disease process [130, 
131, 132, 133, 134]. Hundreds of chemical carcinogens have been identified which have 
the ability to intensively induce malignancy in mammary cells [135].  While carcinogens 
are capable of inducing cellular malignancy, co-carcinogens are capable of inducing cell 
pre-malignancy or enhancing cellular malignancy. Investigations into co-carcinogens, at 
low-doses (pico- to nano-molar), capable of chronically inducing cellular pre-malignancy 
have been overlooked in past studies of sporadic breast cancer development and early 
prevention. In this work I wanted to study whether TCC at physiologically achievable 
doses can act as a co-carcinogen to induce premalignant state of breast cancer.  Also, 
whether, acting as a co-carcinogen, TCC can potentiate or enhance the carcinogenicity 
induced by physiologically relevant dosage of PhIP.  In previous studies it was 
demonstrated that NNK, B[a] P, and PhIP at physiologically achievable doses were 
capable of inducing cellular transformation of human breast epithelial cells to 
premalignant and malignant stages in breast epithelial cells [42, 121].  So we have 
developed a cellular model that tests the potency of various chemicals to induce 
premalignant or malignant carcinogenesis which actually mimics everyday exposure to 
environmental carcinogens such as daily exposure to tobacco smoke in habitual smokers 
[42, 136, 137, 138].  In this approach we use immortalized, non-cancerous human breast 
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epithelial MCF10A cells [139].  MCF10A cells were repeatedly subjected to treatment 
with carcinogens at picomolar to nanomolar concentrations.  This cumulative exposure to 
environmental carcinogens induces breast cells to progressively acquire several 
identifiable cancer-associated properties simulating chronic exposure of breast cells in 
human body to low doses of an environmental carcinogen in daily life.  Using this model 
we repeatedly exposed immortalized, noncancerous, human breast epithelial MCF10A 
cells to TCC and PhIP to nanomolar concentrations and measured the acquisition of 
cancer-associated properties and the underlying molecular mechanisms for induction of 
cellular carcinogenesis as previously done [42, 121, 140, 141, 142, 143, 144].  Our model 
system identifies chemicals capable of inducing premalignant or precancerous and 
malignant or cancerous stages in normal cells.  The model is advantageous in analyzing 
step by step development and progression of carcinogenesis in normal breast epithelial 
cells MCF 10A.  This model subsequently focusses on identifying preventive compounds 
present in our diet that can inhibit multistep carcinogenesis process induced by repeated 
exposures to identified co-carcinogens or carcinogens.  More importantly, this model 
emphasizes the relevance of subduing or preventing the process of carcinogenesis at the 
initial “pre-malignant” stage instead of therapeutically targeting transformed cells.  The 
latter approach can have nonspecific targets and can thus harm the normal body cells too.   
 
1.3 Hallmarks of cancer 
The process of neoplasia involves progressive acquisition of certain token characteristics 
by normal cells to become tumorigenic and these properties are called hallmarks of 
cancer cell [145, 146].  Cancer cells have the ability to grow autonomously and they defy 
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normal control mechanisms that are generally put in place to check cell proliferation and 
growth. Hanahen and Weignberg, in 2000, initially charted out six cancer cell hallmarks 
(Figure 4).  They are as follows: ability to activate signaling pathways responsible for 
conferring on cells the potential to proliferate abnormally, ability to escape restrictions 
imposed on the cell division of normal cells by elements called tumor suppressors, ability 
to  invade surrounding tissues and metastasize to distant organs, ability to acquire the 
potential to replicate with unlimited potential and become immortalized, arrange for 
blood supply for the growing mass of tumor i.e. angiogenesis and avoiding apoptosis.  
Subsequently in the year 2011, some more hallmarks were added to the original list 
which are termed emerging hallmarks and are as follows: ability to alter normal cell 
metabolism to accommodate continuous cancerous growth and secondly, the ability to 
evade normal host immune response including destruction by cells of the immune 
system.  
In the present study, assays were used to determine the acquisition of cancer related 
characteristics by normal cells after their treatment with co-carcinogen and carcinogen. 
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Figure 1.4.  Hallmarks of cancer 
 
  
30 
 
The acquired biological properties that were measured and used as indicators of 
acquisition of cancerous properties included reduced dependence on growth factors, 
anchorage-independent growth, ability to proliferate abnormally, capability to induce 
ROS and activate Erk-Nox cell signaling pathway.  The latter two characteristics drive 
cells towards abnormal proliferation. Lastly, the potential to migrate and invade 
surrounding tissues was also measured.  Cancer cells do not respond to signals that 
usually regulate cell growth and division.  These properties were used as targeted 
endpoints to determine the capability of preventive agents to suppress cellular 
carcinogenesis. 
 
1.4 Detection of Cancer Progression 
 
1.4.1 Reduced dependence on growth factors:  
The cancer cells by definition divide uncontrollably and their proliferation is not 
restricted by the amount of growth stimulatory factors present in their surrounding 
environment.  In addition, growth of cancer cells is not dependent on external stimulatory 
cues i.e. those present in the culture media.  The cancer cells proliferate without any 
checks leading to other cancer cells.  So, cancerous cells grow proficiently even in the 
absence of growth stimulatory signals that normal cells require from their environment.  
Cancer cells do not need stimulation from external signals (in the form of growth factors) 
to multiply [145, 147].  Whereas, in the case of normal cells, there is an absolute 
requirement for the presence of growth stimulatory factors in the culture media or the cell 
surroundings, for the cells to divide and proliferate. In the absence of growth factors, the 
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cells die out by the process of apoptosis. So, when the normal cells gain the capability to 
survive and proliferate under the conditions which lack adequate growth factors, this 
indicates acquisition of a property associated with cancer cells. Hence reduced 
dependence on growth factors is a cancer-associated property [42, 121, 140, 141, 142, 
143, 144].  
 
1.4.2 Anchorage independent growth 
Normal cells require adherence to extracellular matrix for their survival in a multicellular 
setting. In the absence of contacts or adhesion to extracellular matrix cells fail to survive 
and undergo apoptosis [145].  Unusually enhanced cell survival which causes anchorage-
independent cell proliferation is another cancer associated property that can promote 
tumorigenic transformation [145, 146].  For instance, primary fibroblastic cell cultures 
have an absolute requirement for attachment to external surroundings.  So cell lines for 
example, NIH-3T3 cannot grow on agar rose or cell suspension.  But when these cells 
can grow in suspension or on soft agar, they are considered to have acquired the property 
of anchorage-independence highly suggestive of acquisition of cancerous traits [148, 149, 
150].  Anchorage independence gives the ability to cancer cells to form colonies in soft 
agar which can be used to determine progression of cellular carcinogenesis [42, 121, 140, 
141, 142, 143, 144].  
 
1.4.3 Migration and Invasion 
Normal breast cells grow over basement and do not invade or escape through the 
basement membrane. When normal cells become motile and migrate and invade the 
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basement followed by invasion into blood stream or lymphatics, they are thought to have 
acquired cancer related properties. By being motile and invasive cancer cells can escape 
the site of primary tumor formation and via blood or lymphatics reach distant organs and 
tissues and colonize there [145, 152].  
 
1.5 Role of ERK Pathway in Cancer 
Cellular signal transduction involves conveying messages from extracellular environment 
to its intracellular environment through an intricate network of proteins which regulate 
numerous cell processes governing cell fates like cell survival, proliferation, 
differentiation, migration or apoptosis etc.  The cellular signaling mechanism involves 
ligand like factors such as, growth factors, steroid hormone, cytokines and G protein 
receptor ligands in the extracellular environment impinging on cell surface proteins 
called as receptors, and in turn activating them after which ensues a cascade of 
downstream cytoplasmic protein kinase activation ultimately leading to conveying of 
messages to the nucleus.  These protein kinases involved in this signal transduction are 
serine threonine kinases and referred to as mitogen activated protein kinases or MAPKs 
[153].  In mammals, at present 14 MAPKs have been recognized which have been 
allocated to seven groups [154].  Out of these the most studied and conventional MAPKS 
include the following: ERK1/2, JNKs, and p38 isoforms [155].   
However, the most important and widely studied MAPK in breast cancer is ERK1/2 
MAPK pathway [156].  This pathway involves signal transduction via activation of cell 
surface receptors mostly tyrosine kinase receptors followed by activation of 
Ras/Raf/MEK/ERK cascade ultimately conveying signals via transcription factors which 
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regulate expression of a variety of genes [157] (Figure 1.5).  Cell surface receptors most 
commonly involved in breast cancer include tyrosine kinase receptors of the family: 
epidermal growth factor receptors (EGFR).  These include EGFR1, EGFRII, EGFR III 
and EGFR IV.  When appropriate ligand binds to the receptor, dimerization of the 
receptor occurs and the receptor subsequently undergoes auto phosphorylation on 
tyrosine residues in its cytoplasmic domains.  These sites become homing location for 
several key adaptor proteins with SH2 or PTB domains e.g. GrB2 which can contact SOS 
(son of sevenless) with its SH3 domain and activate it.  SOS acts as a guanine nucleotide 
exchange factor and helps Ras to exchange its bound GDP for GTP.  Ras which now is 
able to interact with Raf.  Raf is a serine threonine kinase then undergoes conformational 
change in response to its interaction with Ras and gets activated.  Also, it is postulated 
that other kinases can activate it [158].  It then phosphorylates MEK which is a dual 
specificity kinase which in turn phosphorylates ERK.  ERK upon phosphorylation goes to 
nucleus where it can phosphorylate various transcription factors like AP1, ETS, ELK1 
etc. which drive transcription of genes important for cell proliferation [158].  The Ras 
GTP is reverted back to its inactive Ras GDP form by the hydrolysis of GTP to GDP by 
GTPase activating proteins (GAP) [157].    
  
 
Adapted from Yap et al., ChemMedChem. 2011 January 3; 6(1): 38
Inhibitors of the ERK Signalling Pathway: Towards Novel Anti
Figure 1.5. EGFR-Ras-Erk Pathway
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The importance of MAPK activation in breast cancer tissues was first demonstrated by 
Sivaraman et al. [159].  In their study they studied MAPK pathway activation in tissues 
obtained from primary breast cancer patients and compared these with benign breast 
tissues using western immunoblotting techniques and substrate based MAPK enzyme 
assays.  They found that all tissues from breast cancer patients showed marked activation 
of MAPK signaling. 
Some researchers [160] prepared extracts from 23 human breast cancer tissues and 
normal surrounding areas from the same tissue.  Then using immune-precipitation assay 
and substrate enzyme assay they found that there was up to 2.5 times greater activity of 
ERK1 and ERK 2 in 50 percent of the examined breast cancer samples.  Also, they 
showed increased MEK protein expression and activation for the first time in breast 
cancer tissues. In another study by Muller et al., all of the 131 breast cancers examined 
had significantly higher activation of MAPK protein expression and kinase activity as 
compared to the 18 normal tissues surrounding the breast cancer tissues analyzed [161].  
Even though MAPK protein expression correlated with MAPK activity in only a fraction 
of the tissues analyzed.  Tissues obtained from node positive cancer patients showed 
higher MAPK activity as compared to tumor tissues from the node negative individuals.  
Moreover, patients with a replase of the disease had higher MAPK activity as compared 
with patients with no replase.  So, MAPK activation was suggested to be a potential 
marker for a relapse free survival. Vonlinting et al., demonstrated that in the presence of 
overexpression of EGFR and HER2 receptors, Ras was found to be overly activated in 11 
out of 20 primary breast cancer tissues examined as compared to non-tumor samples 
indicating that in the presence of ligands and overexpression of their cognate receptors 
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Ras upregulation may be the driving force for an activated MAPK pathway, hence 
suggesting a possible mechanism for upregulation of MAPK in breast cancer specimen 
[162].  In an attempt to clarify the mechanisms behind upregulated MAPK activity and 
protein expression in tumor tissues, some people [163], showed that in the primary mouse 
mammary cultures, presence of epidermal growth factor caused activation of MAPK.  
Hence, current research clearly shows the importance of activated ERK Pathway in breast 
cancer [156].  Studies have also shown that ERK pathway activation can result in 
response to an exposure to environmental carcinogens at a high concentration [164].  
Recent research has also shown that long term exposure to low dose of environmental 
carcinogens such as those present in diet, tobacco smoke etc. can induce carcinogenesis 
in normal breast epithelial cells [42, 121, 141], which is accompanied by upregulation of 
MAPK pathway.  Also, there exists a need to assess the potential hazards of a long term 
exposure to various chemicals that humans are exposed to in their day today life, on the 
basis of their ability to cause upregulation of MAPK pathway in normal cells especially 
those of breast tissues.  
 
1.6 Role of Reactive Oxygen Species in Cancer 
Reactive oxygen species are a class of reactive chemicals derived from oxygen and 
generated during mitochondrial respiration and oxidation-reduction enzymatic reactions 
in the cytoplasm.  Main types of ROS include: superoxide anion; hydrogen peroxide; 
hydroxyl radical; hydroxyl ion; and nitric oxide [165, 166].  ROS producing compounds 
have the capability to cause or modulate progressive carcinogenesis induction [167].  As 
is evident by recent research, reactive oxygen species plays a prominent role in 
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tumorigenesis in many organs like in case of prostate cancer [168, 169].  Various sources 
of cellular ROS include mitochondria, peroxisomes and cytochromes.  Exogenous 
sources of ROS generation are exposure to UV radiation, inflammatory processes and 
infectious agents.  ROS thus generated introduces tremendous oxidative stress on the 
cellular machinery leading to damage to DNA, RNA and lipid components of the cell, 
protein denaturation, genomic instability and alteration in gene expression profile.  
Cellular enzyme Nox (NADPH oxidase) is also responsible for generation of ROS.  
Environmental agents capable of generating ROS include benzopyene, PhIP, phorbol 
ester, heterocyclic amines like PhIP, chlorinated compounds, inorganic metals like nickel 
and chromium etc., which can induce oxidative stress and consequent damage to cellular 
machinery, as has been shown in many studies [167].  Studies have documented that non-
genotoxic chemicals may be able to induce carcinogenesis by virtue of their ability to 
induce oxidative stress.  Environmental agents capable of inflicting both acute and 
chronic oxidative insult on the cell have the potential to cause cancer [170].  Most 
frequently encountered ROS induced DNA and RNA lesions include 8-hydoxyguanine 
and 8-hydroxydeoxyguanine [171].  Moreover, 8-hydoxyguanine and 8- 
hydroxydeoxyguanine have been touted as the most detrimental in forming DNA adducts 
and mutations [172].  Studies have described formation of more than 100 different types 
of adducts affecting purine or pyrimidine rings and DNA backbone structures [173, 174, 
175, 176].  It is believed that oxidative damage to DNA machinery in man occurs at an 
alarming rate of 104 lesions/ cell/ day [173, 177].  ROS can not only be produced by 
exposure to high dosage of carcinogens [178], but also, recent studies have shown that 
low dose chronic exposure to environmental carcinogens, especially at their 
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physiologically relevant concentrations, can cause significant ROS production leading to 
DNA damage and breast cellular carcinogenesis [42, 121].  Role of Erk –Nox pathway in 
generating ROS and beast cell carcinogenesis has been shown in some studies but needs 
to be further validated.  Similarly, there is a need to see if low level of ROS generated in 
response to exposure to physiologically achievable doses of chemicals, with which we 
come in contact on a day to day basis, would be able to induce breast cellular 
carcinogenesis. Furthermore, it needs to be determined whether TCC can induce ROS in 
breast cells. 
 
1.7 NADPH Oxidase-1 
Reactive oxygen species is generated by action of family of enzymes called as NADPH 
oxidases [nicotinamide adenine dinucleotide phosphate (NADPH) oxidase or Nox family 
oxidases]. ROS produced by NOX family of enzymes can in turn affect several cellular 
functions like migration, invasion, proliferation etc. Currently there are seven well known 
isoforms of NOX family Nox1 to Nox 5 and DUOX 1-2 [179].  A divergent variety of 
cells in the body are known to express Nox-1 like: epithelial cells, retina, smooth muscle, 
bone cells, endothelium and others[180, 181, 182, 183, 184, 185].  Over expression of 
Nox1 was found to cause cell growth, proliferation, cell transformation and 
tumorigenicity in nude mouse models [186].  Over expression of Nox1 has been reported 
in cases of colon cancer [187, 188].  Nox -1 levels were found to be elevated in breast 
cells chronically exposed to dietary carcinogen PhIP [121].  Nox-1 were found to be over 
expressed in more than 85 percent of breast and 70 percent ovarian tumors and its 
expression levels were tightly regulated by mitochondria. Moreover, deregulation of 
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mitochondrial control over nox-1functioning contributed to ovarian and breast tumors. 
[189].   
 
1.8 Cancer preventive substances in diet 
Due to difference in lifestyle, climatic and environmental conditions including diet in 
different regions of the world, wide variations in incidence of cancer and cancer related 
deaths are noted across different geographical regions of the world [190].  Dynamic 
studies and migrant studies done by various authors have compared cancer rates among 
native and migrant populations in host country and have linked different rates of cancer 
among these two populations to differences in dietary, environmental and other lifestyle 
factors [191, 192].  Diet may contribute to cancer related deaths [193].  A large number 
of studies have studied the link between intake of fruits and vegetable to occurrence of 
cancers of the various organs, in the body including breast cancer [194, 195].  Naturally 
occurring agents such as flavonoids, polyphenols, etc. present readily in fruits, 
vegetables, and spices’ owing to their ability to suppress cancers, have been in sharp 
focus of both general public as well as the scientists world over and, the scientific 
evidence that supports their suspected anti-cancer activities is being explored in the 
current ongoing research.  Recent research has made it clear that the diet plays a pivotal 
role in the arena of cancer prevention [196].  
Various compounds with anti-tumor activity have been identified in different 
kinds of fruits and vegetables [197].  Dithiolthiones and isothiocyanates in high quantities 
are present in cruciferous vegetables and their anti-tumor activity is due to their ability to 
enhance the activity of enzymes involved in cleansing the metabolically harmful forms of 
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carcinogens and xenobiotic substances [198].  The diallyl sulfide and allyl methyl 
trisulfide present in onions and leeks are also involved in inducing enzymatic 
detoxification machinery [199].  Genistin, an isoflavonoid extracted from soyabeans, 
could inhibit enzyme tyrosine kinase activity thus impeding signals downstream of cell 
surface receptors known to be highly upregulated in tumor cells [200].  Compounds with 
anti-oxidant activity, such as carotenoids and xanthophylls, are reported to be present in 
leaves of green vegetables [201].  Beta-carotene present in colored fruits and vegetables 
like mango, carrots pumpkin and papaya, can protect a cell against oxidative damage 
induced by reactive oxygen species [202].  Polyphenolic anti-oxidant flavonoids like 
quercetin, which are present in fruits, vegetables and tea, can facilitate efflux of 
intracellular carcinogens and also activate the cellular enzymatic machinery responsible 
for detoxifying toxins [203, 204, 205].  Fiber rich foods such as vegetables and fruits 
have preventive activity against colon cancer [206].  Intake of a healthful diet consisting 
of large amounts of fruits and vegetables can help thwart cancer development.  
Polyphenolic compounds present in green tea have shown promising anti-cancer activity 
[207, 208, 209, 2010].  Green tea has preventive effect against various types of cancer 
and was shown to be effect in preventing skin cancer in animal models, angiogenesis, 
tumor growth and its invasion and metastasis to distant organs [211, 212, 213, 214, 215].  
Epicatechin gallate (ECG) a flavonoid present in green tea extract can interfere with the 
process of carcinogenesis in a variety of ways including activation of cellular 
detoxification machinery, inhibition of enzyme responsible for producing active form of 
carcinogen like cyp1A1, blocking inflammation and inhibiting metastasis [216, 217, 218, 
219, 220].  Epigallocatechin (EGC) also has numerous preventive properties [221, 222].  
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Epigallocatechin-3-gallate (EGCG), another polyphenolic compound present in green tea, 
has been shown to possess cancer preventive activity which is attributed to its antioxidant 
activity [122].  Hence, by counteracting reactive oxygen species produced by a variety of 
different carcinogens, EGCG was shown to prevent chronic breast cell carcinogenesis 
[42, 121].  It has been used as a therapeutic agent in various types of cancers like cervical 
and bladder cancers.  Grape seed extract (GPSE) is enriched in proanthocyanidins, which 
possesses anti-oxidant activities that were shown in both cell culture studies and animal 
model studies to be responsible for its anti-tumor activities [223, 224, 225, 226].  In 
addition, GPSE prevented mammary carcinogenesis induced by carcinogen 
dimethylbenz[a]anthracene (DMBA). Grape seed proanthocyanidins were found to 
prevent chronic breast cell carcinogenesis induced by NNK ans B[a]P [141].  
This study focusses on the significance of naturally occurring compounds 
including those that can be taken easily through daily diet like curcumin, and others like 
Mimosine and Ergosterol, in prevention of sporadic breast cancer and more specifically 
chronic breast cell carcinogenesis.   
 
1.8.1 Curcumin  
Indian yellow herb turmeric derived from Curcuma longa, has been commonly used since 
ancient times in Asian food diets as a yellow coloring powder and spice [227, 228, 229].  
Turmeric mainly contains the following three curcuminoids: diferuloylmethane; 
demethoxycurcumin, and bisdemethoxycurcumin, along with volatile oils (tumerone, 
atlantone, and zingiberone), sugars, proteins, and resins [230].  Curcumin, is the major 
phenolic curcuminoid in the extracts made from turmeric and the one which is 
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responsible for the yellow color of turmeric.  Moreover, since ages curcumin has been 
used in the traditional Indian medicine to treat cancer, rheumatic disorders, inflammation, 
gastrointestinal and ocular diseases [229, 231, 230].  Curcumin has been shown to inhibit 
proliferation of triple negative MDA-MB-231 breast cancer cells by inhibiting EGFR 
signaling pathway with down regulation of pERK1/2 and pEGFR protein expression 
[232].  MDA-MB-231 cells showed slower proliferation rates after treatment with 
curcumin.  In addition, curcumin treatment also caused these cells to undergo cell cycle 
arrest at the G2/M stage and subsequently apoptosis. Also, cell cycle inhibitor, p21, was 
found to be over expressed along with an elevation of bax to bcl2 ratio in these cells 
[233].  It has been shown that curcumin is able to inhibit growth and metastasis of breast 
cancer cells in vitro [234, 235] and in vivo [235].  Curcumin was able to inhibit the in 
vitro migration in MDA-MB-231 cells through down-regulating the protein expression of 
NF-kappaB [234].  Curcumin has been shown to limit the metastatic potential of triple 
negative breast cancer cell lines [233].  In clinical trials, curcumin treatment is being 
applied to a number of patients with breast cancer, rheumatoid arthritis, Alzheimer's 
disease, colorectal cancer, psoriatic, etc.  Several of these clinical trials have reported the 
curcumin treatment to be safe and effective [230, 236, 237].  Curcumin can target and 
affect expression of a variety of proteins including those involved in cell survival, 
proliferation, migration, invasion, and angiogenesis.  Thus, there exists an extensive 
evidence substantiating curcumin’s capability as an anticancer agent in a wide variety of 
tumors and, it has been shown to inhibit the proliferation of tumor cells in vitro, can 
suppress carcinogenesis in rodents, and has been shown to decrease growth of human 
tumors in both orthotopic and xenograft tumor models [237].  Curcumin has been shown 
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to suppress mutagenic effects induced by a wide variety of carcinogens [238, 239, 240].  
Curcumin was shown to inhibit benzo[a]pyerene-induced tumorigenesis in fore stomach 
in mouse models [238, 241], genotoxicity induced by cooked food heterocyclic amines in 
Salmonella typhimurium strains [240], and bio activation of benzo[a]pyerene diol in oral 
squamous carcinoma cells [242].  However, the activity of curcumin in prevention of 
sporadic breast cancer has not been investigated.  Moreover, despite its efficacy and 
potential as a therapeutic anticancer agent, it is yet to be approved as a therapeutic agent 
because of its poor bioavailability [243, 244, 245].  But the use of various adjuvants like 
piperine which inhibits hepatic and intestinal glucuridation machinery, have been shown 
to dramatically improve bioavailablity of curcumin [245, 246].  Similarly, nanoparticle 
based delivery systems [247] and liposomal drug delivery subsystem has been shown to 
be promising agents in improving bioavailability of curcumin.  Liposomal curcumin was 
shown to inhibit pancreatic carcinoma growth and angiogenesis in in vivo tumor models 
[248].  Curcumin structural analogues have also been developed to enhance curcumin 
bioavailability. Curcumin analogues which have no β-diketone moiety such as mono-
carbonyl analogs could enhance its bioavailability and stability [249]. 
 
1.8.2 Ergosterol 
Ergosterol forms a major constituent of fungal cell membrane.  Its structure is shown in 
Figure 1.6.  It plays a hormone like role in fungal cells and stimulates growth of fungus.  
The antitumor activity of ergosterol might be due to direct inhibition of angiogenesis 
induced by solid tumors [250].  Ergosterol extracted from Japanese edible mushroom 
Hypsizigus marmoreus showed inhibitory activity against 12-O-tetradecanoylphorbol-13-
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acetate (TPA) induced ear inflammation and tumor promotion in mice in a two stage 
experimental carcinogenesis study and hence could be used as a potential anticancer 
agent [251].  Ergosterol Peroxide (EP) is found in lichens and mushrooms and it 
possesses immunosuppressive anti-viral, anti-inflammatory and anti-tumor activities 
[252, 253, 254, 255, 256].  Ergosterol peroxide present in oil rich fraction isolated from 
Ganoderma lucidum showed promising results in overcoming the drug-resistance of 
tumor cells attributed to the expression of miR-378 [257].  Ergosterol peroxide exhibits 
anticancer activity in multiple myeloma U266 cells.  It was shown to be an anti-cancer 
agent which targets JAK2/STAT3 signaling pathway and inhibits angiogenesis against 
multiple myeloma cells. However, there is paucity of knowledge regarding the ability of 
ergosterol to act as a preventive agent in cases of breast cancer. 
 
1.8.3 Mimosine 
 
Mimosine or leucenol is an alkaloid, β-3-hydroxy-4 pyridone amino acid which is 
chemically very similar to tyrosine.  Its structure is shown in Figure 1.6.  It was initially 
isolated from Mimosa pudica and is found to occur in some members of genus Mimosa 
and all members of the related genus Leucaena [258]. 
  It is a non-protein, plant origin free amino acid that is toxic to non-ruminants and un-
adapted ruminants.  Mimosine is an iron chelator and that inhibits DNA synthesis and 
mammalian cell proliferation by blocking cell cycle at the late G1 phase [259, 260, 261, 
262].  It has been shown to inhibit cell proliferation in prostate carcinoma cells [263].  
Mimosine was specifically shown to inhibit cyclin D1 expression [264], and upregulate 
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the protein expression levels of p27 [265].  In vivo studies have also demonstrated that it 
has an anticancer effect on human lung cancer xenografts [266].  Studies have been 
conducted that gave an evidence of the ability of mimosine to suppress the growth of 
human pancreatic cancer xenografts that were subcutaneously transplanted in nude mice 
and a flow cytometric analysis of the tumor cells yielded a significantly increased sub-G1 
fraction indicating occurrence of apoptosis [267].  Since its role in inhibiting cancer of 
breast cells has not been studied, this study was done to determine if Mimosine could 
inhibit breast cellular carcinogenesis.   
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Figure 1.6 Chemical structures of preventive agents   
Curcumin Mimosine 
Ergosterol 
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1.9 Hypothesis and Objective 
I have already discussed that more than 85% of breast cancers are sporadic and 
attributable to long-term exposure to small quantities of environmental carcinogenic 
agents that progressively induce non-cancerous cells to pre-malignancy to malignancy in 
a multi-year, multi-step, and multi-path disease process.  Carcinogens are capable of 
inducing cellular malignancy, and co-carcinogens are capable of inducing cell pre-
malignancy or enhancing cellular malignancy.  Very few studies have been done to 
investigate the potential of co-carcinogens to induce the state of cellular pre-malignancy 
or enhance carcinogenicity of other known carcinogens.  There are a plethora of 
chemicals that humans are exposed to daily, however, the effects of their exposure on 
human health are largely unknown.  Many such chemicals possess the hitherto unknown 
capacity to act as mitogens, induce cellular damage and capability to act as co-
carcinogens in initiation and progression of various kinds of cancers including breast 
cancer.  Hence, there exists a need to characterize such chemicals on the basis of their 
potency to induce premalignant or malignant breast cell carcinogenesis.  Moreover, since 
exposure to some of these potential carcinogens cannot be avoided, there is an imminent 
need to search for compounds occurring in nature, which have the preventive activity to 
thwart the process of carcinogenesis initiated by exposure to carcinogens or co-
carcinogens.  Furthermore, early prevention of breast cancer obviates the need for 
therapeutics and its subsequent complications.  Triclocarban is a chemical to which body 
is exposed via a number of ways everyday viz. through shower, hand washes, antiseptics, 
deodorants etc.  Though, recently there has been a lot of focused research to determine 
the effects of TCC on human health, yet the potential of TCC to act as a co-carcinogen 
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has not been addressed so far.  Cooked meat carcinogen PhIP has been shown to cause 
breast carcinogenesis. But whether certain co-carcinogens can enhance the 
carcinogenicity of PhIP when body is exposed to them simultaneously, this has not been 
verified till date.  So, the cumulative impact of a bodily co-exposure of PhIP and TCC 
through different unavoidable sources on breast cells has not been addressed before.  
Also, there is a relative lack of work seeking to uncover the potential of naturally 
occurring preventive agents that can counteract the role of co-carcinogens and 
carcinogens and block progression of premalignant breast cell carcinogenesis.  Hence to 
address the above needs this study was undertaken with the following central hypothesis:  
Long-term exposure to TCC can cause breast cell carcinogenesis and co-exposure to TCC 
and PhIP can enhance PhIP-induced breast cell carcinogenesis  
Then working towards the central hypothesis the study was divided into four broad 
objectives:  
 To determine if chronic exposure to physiologically achievable doses of TCC can 
cause breast epithelial cells to acquire the cancer-associated properties. 
 To study potential of curcumin in intervention of TCC-induced breast cell 
carcinogenesis. 
 To determine if TCC can enhance PhIP-induced breast cell carcinogenesis. 
 To determine whether mimosine and ergosterol can block breast cell 
carcinogenesis induced by co-treatment of TCC and PhIP. 
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ER: Estrogen resceptor, PR: Progestron receptor, Her2; Human epidermal growth factor 
receptor2  
TABLE 1: MICOARRAY CLASSIFICATION OF BREAST CANCER (MODIFIED 
FROM Krishnamurthy et al., 2012) 
Subtypes ER/PR /Her2 
Status 
Other Immuno-
Histochemical 
Features 
Cell Of Origin Other 
Characters 
Luminal A ER or PR +ve or 
both Her2 -ve 
keratin 8/18 +ve luminal epithelial 
cell 
Best prognosis 
Higher survival 
rate 
Luminal B ER or PR +ve or 
both, Her2 +ve 
keratin 8/18 +ve luminal epithelial 
cell 
Higher tumor 
grade, Poorer 
prognosis 
Basal Like ER/PR –ve,      
Her2 +ve/-ve 
keratin 5/6/17 +ve 
EGFR +ve 
Basal/myoepithelial/
bipotentl progenitor 
15% 
Her 2+ ER/PR –ve,      
Her2 +ve 
- Late luminal  
progenitor 
20-25%, Poorer 
grade and 
prognosis 
Normal 
Breast Like 
Tumors that 
don’t fill any of 
the other 
categories 
- Luminal epithelial 
cell 
6-10%, associated 
with 
fibroadenomas, 
Good prognosis 
Claudin Low All –ve mesenchymal markers Stem cells Typically triple –
ve 5-10% of all 
tumors 
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Table 2:List of risk factors  
Hereditary and non-modifiable risk 
factors 
Environmental and modifiable risk factors 
 
Age Physical inactivity 
 
Gender Alcohol 
 
Genetic factors (BRCA1 and BRCA2 
gene mutation) 
Smoking 
 
Race Unhealthy diet 
 
Menstrual and reproductive factors Exposure to ionizing radiation 
 
Proliferative breast conditions Hormonal replacement therapy 
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Chapter 2 
 
Induction of Human Breast Cell Carcinogenesis by Triclocarban 
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Research described in this chapter is slightly modified version of an article that has been 
submitted to Molecular Carcinogenesis in April, 2013  
 Induction of Human Breast Cell Carcinogenesis by Triclocarban by 
Shilpa Sood, Shambhunath Choudhary, and Hwa-Chain Robert Wang  
 
In this paper “our” and “we” refers to me and co-authors. My contribution in the 
paper includes the following: 
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) 
Designing experiments (4) understanding the literature and interpretation of the 
results (5) providing comprehensive structure to the paper (6) Preparation of the 
graphs and figures (7) Writing and editing 
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2.1 Abstract 
 More than 85% of breast cancers are sporadic and attributable to long-term 
exposure to environmental carcinogens and co-carcinogens.  To identify co-carcinogens 
with abilities to induce cellular pre-malignancy, we studied the activity of triclocarban 
(TCC), an antimicrobial agent commonly used in household and personal care products.  
Here, we demonstrated, for the first time, that chronic exposure to TCC at 
physiologically-achievable nanomolar concentrations resulted in progressive 
carcinogenesis of human breast cells from non-cancerous to pre-malignant.  Pre-
malignant carcinogenesis was measured by increasingly-acquired cancer-associated 
properties of reduced dependence on growth factors, anchorage-independent growth and 
increased cell proliferation, without acquisition of cellular tumorigenicity.  Long-term 
TCC exposure also induced constitutive activation of the Erk-Nox pathway and increases 
of reactive oxygen species (ROS) in cells.  A single TCC exposure induced transient 
induction of the Erk-Nox pathway, ROS elevation, increased cell proliferation, and DNA 
damage in not only non-cancerous breast cells but also breast and bladder cancer cells.  
Using these constitutively- and transiently-induced changes as endpoints, we revealed 
that non-cytotoxic curcumin, a component of turmeric extracted from the Indian herb 
Curcuma longa, was effective in intervention of TCC-induced cellular pre-malignancy.  
Our results lead us to suggest that the co-carcinogenic potential of TCC should be 
seriously considered in epidemiological studies to reveal the significance of TCC in the 
development of sporadic breast cancer.  Using TCC-induced transient and constitutive 
endpoints as targets will likely help identify non-cytotoxic preventive agents, such as 
curcumin, effective in suppressing TCC-induced cellular pre-malignancy.    
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2.2 Introduction 
 Breast cancer is the most common cancer and the second leading cause of cancer 
deaths among women in northern America and Europe [1].  More than 85% of breast 
cancers are sporadic and attributable to long-term exposure to small quantities of 
environmental carcinogenic agents that progressively induce non-cancerous cells to pre-
malignancy to malignancy in a multi-year, multi-step, and multi-path disease process [2–
5].  Over 200 chemical mammary carcinogens have been identified by measuring their 
ability to intensively induce malignant cells or tissues [6].  While carcinogens are capable 
of inducing cellular malignancy, co-carcinogens are capable of inducing cell pre-
malignancy or enhancing cellular malignancy.  Investigations into co-carcinogens, at 
low-doses (pico- to nano-molar), capable of chronically inducing cellular pre-malignancy 
have been overlooked in past studies of sporadic breast cancer development and early 
prevention.  
 One potential co-carcinogen, triclocarban (TCC, or 3,4,4'-trichlorocarbanilide) is 
a lipophilic, antimicrobial compound widely used in household and personal care 
products, such as disinfectants, soaps, deodorants, detergents, and wipes, etc [7].  TCC 
exhibits endocrine-disrupting activity to induce estradiol-dependent activation of estrogen 
receptor (ER)-responsive gene expression but alone lacks agonistic activity [8,9].  Direct 
dermal exposure to TCC results in transdermal absorption and accumulation in 
underlying tissues, including mammary tissues [10].  More specifically, a single whole-
body shower using TCC-containing soap results in blood levels as high as ~500 nmol/L 
within 3 h [11,12].  In addition, TCC is resistant to both wastewater chemical and 
biological treatments, and agricultural use of TCC-containing biosolids renders TCC into 
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the food chain, thus increasing human exposure to TCC [7,13–15].  Although the role of 
TCC in increasing breast cancer risk has been questioned, it has not yet been addressed.  
It is imperative to clarify the role of low-dose TCC in sporadic breast cancer development 
and to identify effective agents for intervention.   
 One possible hindrance for such sporadic breast cancer development is curcumin, 
the major phenolic compound in turmeric extracts.  Curcumin has been used in Asian 
countries for hundred years to treat various diseases, including gastrointestinal, retinal, 
and rheumatic disorders, as well as inflammation and cancer [16–20].  It has been shown 
that curcumin is able to inhibit growth and metastasis of breast cancer cells both in vitro 
and in vivo [21–23].  Curcumin has also been shown to inhibit stomach tumors induced 
by benzo[a]pyerene (B[a]P) in mice [24,25], genotoxicity induced by heterocyclic amines 
in Salmonella typhimurium [26], and bioactivation of B[a]P-diol in oral squamous 
carcinoma cells [27].  However, the activity of curcumin in prevention of sporadic breast 
cancer has not been addressed. 
 We have developed a cellular model to identify carcinogenic agents, at 
physiologically-achievable levels, capable of chronically inducing human breast 
epithelial cell carcinogenesis [28–33].  We revealed that and cellular, biochemical, and 
molecular changes transiently induced by single exposure to carcinogenic agents, and 
changes constitutively induced by cumulative exposures play essential roles in induction 
of cellular carcinogenesis and maintenance of acquired cancer-associated properties, 
respectively [28–33].  We then used these transient and constitutive changes/endpoints as 
targets to identify non-cytotoxic agents, such as green tea catechins and grape seed 
extract, effective in intervention of cellular carcinogenesis [29–36].  In this 
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communication, we used our model system, for the first time, to reveal the ability of 
TCC, at nanomolar levels, to induce breast cell pre-malignancy.  We also studied the 
activity of curcumin, at non-cytotoxic levels, effective in intervention of TCC-induced 
cellular carcinogenesis.  
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2.3 Materials and methods 
2.3.1 Cell Cultures and Reagents 
 MCF10A (American Type Culture Collection [ATCC], Rockville, MD) and 
derived cell lines were maintained in complete (CM) medium (1:1 mixture of DMEM 
and HAM's F12, supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL insulin, 
0.5 µg/mL hydrocortisol, 20 ng/mL epidermal growth factor, and 5% horse serum) [28–
36].  Human breast cancer MCF7 and urinary bladder carcinoma J82 cells (ATCC) were 
maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum [33].  
All cultures were maintained in medium supplemented with 100 U/mL penicillin and 100 
µg/mL streptomycin in 5% CO2 at 37°C.  Stock aqueous solutions of TCC (Sigma-
Aldrich, St. Louis, MO), chloromethyl-dichlorodihydrofluorescein-diacetate (CM-
H2DCF-DA) (Invitrogen, Carlsbad, CA), U0126 (Cell Signaling, Beverly, MA), and 
curcumin (MP Biomedicals, Solon, Ohio) were prepared in DMSO and diluted in culture 
medium.  Stock aqueous solutions of N-acetyl-L-cysteine (NAC) (Alexis, San Diego, 
CA) were prepared in H2O and diluted in culture medium for assays.  
 
2.3.2 Chronic Induction of Cellular Carcinogenesis 
 Twenty-four h after each subculturing, MCF10A cells were exposed to TCC for 
48 h, as one cycle of exposure for 10 to 20 cycles; cultures were subcultured every 3 d 
[28–33].  After exposures to TCC, cells were assayed to detect acquired cancer-
associated properties. 
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2.3.3 Reduced dependence on growth factors 
 Five × 103 cells were seeded in 60-mm culture dishes and maintained in low-
mitogen (LM) medium containing reduced total serum and mitogenic additives to 2% of 
the concentration formulated in CM medium.  Cell colonies (≥ 0.5 mm diameter) grown 
in LM medium were counted microscopically [29–33]. 
 
2.3.4 Anchorage-independent Growth 
 Five x 103 cells were mixed with soft-agar consisting of 0.4% SeaPlaque agarose 
(Sigma-Aldrich) in a mixture (1:1) of CM medium with 3 d conditioned medium 
prepared from MCF10A cultures, plated on top of the 2% SeaPlaque agarose base layer 
in a 60-mm culture dish, and maintained for 20 d to develop cell clones.  Cell colonies (≥ 
0.1 mm diameter) grown in soft-agar were counted microscopically [29–33]. 
 
2.3.5 Cell Viability Assay 
 A Methyl Thiazolyl Tetrazolium (MTT) assay kit (ATCC) was used to measure 
cell survivability in cultures.  Five x 103 cells were seeded into each well of 96-well 
culture plates for 24 h.  After indicated treatments, cells were incubated with MTT 
Reagent for 4 h, followed by incubation with detergent reagent for 24 h.  Reduced MTT 
reagent in cultures was quantified with an ELISA reader (Bio-Tek, Winooski, VT) 
[37,38]. 
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2.3.6 Cell Proliferation 
 Cell proliferation was determined by of 5-bromo-2’-deoxyuridine (BrdU) 
incorporation into cellular DNA using the BrdU cell proliferation ELISA kit (Roche, 
Indianapolis, IN).  Five x 103 cells were seeded into each well of 96-well culture plates 
for 24 h.  After treatment, cells were labeled with BrdU for 12 h, fixed, incubated with 
peroxidase-conjugated BrdU-specific antibodies, and stained with peroxidase substrate.  
Quantification of BrdU-labeled cells was determined with an ELISA reader (Bio-Tek) 
[37–39]. 
 
2.3.7 Intracellular ROS 
 As performed previously [32–36,40], cells were incubated with 5 µmol/L CM-
H2DCF-DA for 1 h to detect ROS level by flow cytometry; the mean fluorescence 
intensity of DCF was quantified using Multicycle software (Phoenix).  
 
2.3.8 DNA Damage 
 DNA damage was measured by a comet assay [33,41].  Cells were mixed with 1% 
low-melting agarose and placed on agarose-coated slides.  Slides were then immersed in 
lysis solution (1.2 mol/L NaCl, 100 mmol/L Na2EDTA, 1% Triton X-100, and 0.3 
nmol/L NaOH, pH 13) at 25°C for 1 h and rinsed three times with alkaline buffer (2 
mmol/L Na2EDTA and 300 mmol/L NaOH) for 20 min each.  After electrophoresis in the 
same alkaline buffer at 20V for 30 min, slides were stained with 2.5 µg/mL of propidium 
iodide for 20 min and examined with a Zeiss fluorescence microscope (Thornwood, NY) 
equipped with an excitation filter of 546 nm and barrier filter of 590 nm.  Fifty nuclei per 
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slide were scored for tail moment (% of DNA in the tail × tail length) using CometScore 
software (Tritek, USA).  
 
2.3.9 Western Immunoblotting 
 Equal amounts of cellular proteins were resolved by electrophoresis in 10% SDS-
polyacrylamide gels and transferred to nitrocellulose filters for immunoblotting [42–44].  
Specific antibodies were used to detect H-Ras, phosphorylated Mek (p-Mek), Mek, 
phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, and β-Actin (Santa Cruz 
Biotechnology, Santa Cruz, CA).  Antigen-antibody complexes on filters were detected 
by the Supersignal chemiluminescence kit (Pierce, Rockford, IL). 
 
2.3.10 Statistical Analysis 
 The Student t test was used to analyze statistical significance, indicated by * P < 
0.05, ** P < 0.01, *** P < 0.001; a P value of ≤ 0.05 was considered significant. 
 
2.4 Results & Discussion 
 
2.4.1 Induction of Breast Cell Carcinogenesis by TCC 
 To investigate the ability of TCC to induce breast cell carcinogenesis, we 
repeatedly exposed MCF10A cells to TCC at various concentrations for 10 and 20 cycles.  
Normal epithelial cells require growth factors to grow and survive, and cell adhesion to 
extracellular matrix is essential for survival in a multi-cellular environment; in contrast, 
cancerous cells acquire the abilities of a reduced dependence on growth factors and an 
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independence from cell adhesion to matrix (anchorage-independent growth) to survive 
[45,46].  We used these two cancer-associated properties as constitutive endpoints to 
measure the progress of cellular carcinogenesis induced by cumulative exposures to 
various carcinogenic agents [32,33].  As shown in Figure 2.1A and 2.1B, higher numbers 
of survived colonies, which acquired both cancer-associated properties, remained in 
cultures exposed to TCC at higher concentrations than in cultures exposed to lower 
concentrations (1000 > 500 > 200 nmol/L), and higher numbers of colonies survived in 
cultures exposed to TCC for 20 cycles than in cultures exposed for 10 cycles.  These 
results indicate that cumulative exposures of MCF10A cells to TCC resulted in 
progressively-increased acquisition of these two cancer-associated properties/constitutive 
endpoints in a dose- and exposure-dependent manner.  
 Our previous studies [32,33] revealed that the Erk-Nox pathway, as a constitutive 
biochemical endpoint, is involved in maintaining acquired cancer-associated properties of 
pre-malignant and malignant breast cells induced by chronic exposure to carcinogenic 
agents, including B[a]P, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).  Investigating signaling 
pathways involved in TCC-induced cellular carcinogenesis, we detected that As shown in 
Figure 1C, chronic exposure to TCC also resulted in constitutive activation of the Erk-
Nox pathway, indexed by increased phosphorylation of Erk1/2 and increased level of 
Nox-1 (Figure 2.1C).  The level of induced Erk-Nox pathway (Figure 2.1C) was in 
concert with the degree of acquired cancer-associated properties (2.1A & B).    
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Legend for Figure 2.1.  Dose- and exposure-dependent induction of carcinogenesis 
by TCC.  MCF10A cells were repeatedly exposed to DMSO (0) or 200, 500, or 1000 
nmol/L (nM) TCC for 10 and 20 cycles.  (A) To determine acquisition of the cancer-
associated property of reduced dependence on growth factors (RDGF), cells were 
maintained in LM medium.  (B) To determine acquisition of the cancer-associated 
property of anchorage-independent growth (AIG), cells were seeded in soft-agar.  Cell 
colonies were counted microscopically.  Columns, mean of triplicates; bars, SD.  
Statistical significance is indicated by ** P < 0.01, *** P < 0.001.  (C) Cell lysates 
isolated from cultures exposed to TCC for 20 cycles were analyzed by immunoblotting 
using specific antibodies to detect levels of phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, 
and Nox-1, with β-Actin as a control; these levels were quantified by densitometry.  The 
level of specific phosphorylation of Erk1/2 (p-Erk/Erk) was calculated by normalizing 
the level of p-Erk1/2 with the level of Erk1/2, the level set in control cells (0 nM TCC) as 
1 (X, arbitrary unit).  The level of Nox-1 (Nox/Actin) was calculated by normalizing with 
the level of β-Actin, the level set in control cells as 1 (X, arbitrary unit).  All results are 
representative of three independent experiments.
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Figure 2.1. Dose- and exposure-dependent induction of carcinogenesis by TCC 
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These results are consistent with our published findings of constitutive endpoints induced 
by B[a]P, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and/or 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in breast cell carcinogenesis [32,33]; thus, 
the cancer-associated properties of reduced dependence on growth factors and anchorage-
independent growth can also be used as constitutive cellular endpoints in the 
measurement of TCC’s ability to induce cellular carcinogenesis, and the Erk-Nox 
pathway can be used as a constitutive biochemical endpoint to detect TCC-induced 
cellular carcinogenesis.    
 
2.4.2 Transient Endpoints Induced by TCC 
 Our previous studies revealed that a single exposure of MCF10A cells to B[a]P, 
NNK, or PhIP induces transient endpoints, including Erk-Nox pathway activation, ROS 
elevation, increased cell proliferation, and DNA damage, which play essential roles in 
initiation of carcinogenesis in each exposure, accounting for the mechanisms of these 
agents in chronic induction of carcinogenesis [32,33].  To detect transient endpoints 
induced by TCC, we exposed MCF10A cells to 200 nmol/L TCC for 48 h.  Because 
studies showed that a single whole-body shower using TCC-containing soap frequently 
results in blood levels at ~200 nmol/L [11,12], we chose to use the physiologically-
achievable level of 200 nmol/L TCC to study its activity and mechanisms in induction of 
cellular carcinogenesis.   
 As shown in Figure 2.2A, phosphorylation of Erk1/2 was transiently induced, and 
the maximal level of phosphorylated Erk1/2 was reached in 24 h, indicating a transient 
activation of the Erk pathway by TCC.    
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Legend for Figure 2.2.  Transient endpoints induced by TCC.  (A) MCF10A (10A) 
cells were treated with 200 nmol/L TCC (T) for the indicated periods.  (B1 to B5) 10A 
cells were exposed to TCC in the absence or presence of 10 µmol/L U0126 (U) or 5 
mmol/L NAC (N) for 24 h.  (C1 to C3) MCF7 and J82 cells were treated with 200 
nmol/L TCC for 24 h.  (A, B1, B2, & C1) Cell lysates were prepared and analyzed by 
immunoblotting to detect levels of p-Erk1/2, Erk1/2, and Nox-1, with β-Actin as a 
control, and these levels were quantified by densitometry.  The level of specific 
phosphorylation of Erk1/2 (p-Erk/Erk) was calculated by normalizing the level of p-
Erk1/2 with the level of Erk1/2, then the level set in control cells as 1 (X, arbitrary unit).  
The level of Nox-1 (Nox/Actin) was calculated by normalizing with the level of β-Actin 
and the level set in control cells as 1 (X, arbitrary unit).  (B3 & C2) Relative ROS levels 
were measured with CM-H2DCF-DA labeling and normalized by the fluorescence 
intensity determined in control cells, set as 1 (X, arbitrary unit).  (B4) Relative cell 
proliferation was determined and normalized by the value of BrdU detected in control 
cells, set as 100%.  (B5 & C3) Relative DNA damage was measured by a comet assay 
and normalized by the value of average tail moment determined in control cells, set as 1 
(X, arbitrary unit).  Representative images of DNA damage in the comet assay are shown 
in B5.  Columns, mean of triplicates; bars, SD.  Statistical significance is indicated by * P 
< 0.05, ** P < 0.01.  All results are representative of three independent experiments. 
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Figure 2.2 Transient endpoints induced by TCC  
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Using the Mek inhibitor U0126 to block the Erk pathway, Nox-1 was reduced to a lower 
level than in parental cells and TCC-exposed cells (Figure 2.2B1), indicating that TCC 
induced Nox-1 through activation of the Erk pathway, thereby verifying the ability of 
TCC to induce transient activation of the Erk-Nox pathway.  Using NAC to block ROS, 
we detected that the Erk-Nox pathway was suppressed in TCC-exposed cells (Figure 
2.2B2), indicating ROS was induced by TCC in activation of the Erk-Nox pathway.  
Additionally, blocking the Erk-Nox pathway by U0126 resulted in significant reduction 
of TCC-induced ROS (Figure 2B3), suppression of ROS by NAC or U0126 resulted in 
significant reduction of TCC-induced cell proliferation (Figure 2.2B4), and blockage of 
the Erk-Nox pathway or ROS resulted in suppression of TCC-induced DNA damage 
(Figure 2.2B5).  These results indicate that TCC was able to induce the Erk-Nox pathway 
and Nox-dependent ROS elevation, as well as Nox-independent ROS elevation to induce 
increased cell proliferation and DNA damage.  TCC-induced, Nox-independent ROS also 
played a role in activation of the Erk-Nox pathway.   
 To address if TCC’s ability to induce these transient endpoints was limited to the 
ER-negative MCF10A cells, we treated human breast cancer ER-positive MCF7 cells and 
urinary bladder cancer J82 cells with TCC.  We detected that TCC was able to induce the 
Erk-Nox pathway (Figure 2C1), ROS elevation (2C2), and DNA damage (2C3) in both 
types of human cancer cells.  The results indicate that TCC-induced transient endpoints 
were not specific to breast cells nor to ER status.   
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2.4.3 Constitutive Endpoints Induced by TCC 
 To assess carcinogenic potency of TCC-exposed breast cells, we used the 
tumorigenic P-20 cell line, which resulted from cumulative exposure of MCF10A cells to 
PhIP for 20 cycles [33], and a highly-tumorigenic, oncogenic Ras-expressing MCF10A-
Ras cell line [33,44] as controls.  As performed previously, cumulative exposures of 
MCF10A cells to 200 nmol/L TCC for 10 and 20 cycles resulted in T-10 and T-20 cell 
lines, respectively.  Then, we measured degrees of constitutive endpoints acquired by T-
10 and T-20 cells in comparison with P-20 and MCF10A-Ras cells.  As shown in Figure 
3, the constitutive endpoints of reduced dependence on growth factors (2.3A), anchorage-
independent growth (2.3B), increased cell proliferation (3C), ROS elevation (2.3D), and 
Mek-Erk-Nox pathway activation (3E) were increasingly induced in T-10 and T-20 cells 
in an exposure-dependent manner; however, none of these constitutive endpoints was 
induced to a comparable level to those acquired by tumorigenic P-20 and MCF10A-Ras 
cells.  Inoculation of T-20 cells into mammary fat pads of immunocompromised nu/nu 
mice did not result in any xenograft tumors in 90 days in contrast to xenograft tumors 
derived from P-20 and MCF10A-Ras cells, indicating that the T-20 cell line was not 
tumorigenic (data not shown).  These results indicate that long-term exposure to TCC 
was able to induce cellular pre-malignancy.    
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Legend for Figure 2.3.  Constitutive endpoints induced by exposure to TCC.  
MCF10A (10A) cells were repeatedly exposed to 200 nmol/L TCC for 10 and 20 cycles, 
resulting in T-10 and T-20 cell lines, respectively.  10A cells were repeated exposed to 10 
nM PhIP for 20 cycles to generate P-20 cells.  10A cells were stably transfected to 
ectopically express oncogenic H-Ras, resulting in the MCF10A-Ras cell line (Ras).  (A) 
Cells were maintained in LM medium to determine acquired levels of reduced 
dependence on growth factors (RDGF).  (B) Cells were seeded in soft-agar to determine 
acquired levels of anchorage-independent growth (AIG).  (C) Relative cell proliferation 
was determined and normalized by the value of BrdU detected in control parental cells, 
set as 100%.  (D) Relative ROS levels were measured with CM-H2DCF-DA labeling and 
normalized by the fluorescence intensity determined in control parental cells, set as 1 (X, 
arbitrary unit).  (E) Cell lysates were prepared and analyzed by immunoblotting to detect 
levels of p-Mek, Mek, p-Erk1/2, Erk1/2, and Nox-1, with β-Actin as a control, and these 
levels were quantified by densitometry.  The levels of specific phosphorylation of Mek 
(p-Mek/Mek) and Erk1/2 (p-Erk/Erk) were calculated by normalizing the level of p-Mek 
and p-Erk1/2 with the level of Mek and Erk1/2, respectively, then the level set in control 
parental cells as 1 (X, arbitrary unit).  The level of Nox-1 (Nox/Actin) was calculated by 
normalizing with the level of β-Actin and the level set in control parental cells as 1 (X, 
arbitrary unit).  Columns, mean of triplicates; bars, SD.  Statistical significance is 
indicated by * P < 0.05, ** P < 0.01, *** P < 0.001.  All results are representative of 
three independent experiments.
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Figure 2.3: Constitutive endpoints induced by exposure to TCC.  
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2.4.4 Intervention of TCC-induced Carcinogenesis by Curcumin 
 Early intervention of cellular carcinogenesis from a non-cancerous stage to pre-
malignant stages conceivably contributes to effective cancer prevention [2].  To identify 
preventive agents effective in intervention of cellular pre-malignancy induced by chronic 
exposure to TCC, we pursued agents, at non-cytotoxic levels, capable of blocking TCC-
induced transient and constitutive endpoints in MCF10A cells.  As shown in Figure 4A, 
treatment of cells with curcumin at 10 and 20 µmol/L for 72 h resulted in significant 
reduction of cell viability, but 0.1 or 1 µmol/L did not result in any detectable reduction 
of cell viability.  We used curcumin at the non-cytotoxic concentration of 1 µmol/L in the 
following studies.  
 In studying if curcumin was able to block TCC-induced transient endpoints, we 
detected that co-exposure MCF10A cells to 200 nmol/L TCC ane1 µmol/L curcumin 
reduced TCC-induced activation of the Erk-Nox pathway (Figure 2.4B1).  Curcumin 
treatment also significantly reduced TCC-induced transient endpoints of ROS elevation 
(Figure B2), increased cell proliferation (B3), and DNA damage (B4).  These results 
indicate that co-exposure to curcumin interfered in TCC-induced initiation of cellular 
carcinogenesis in a single exposure.  After 10 cycles of exposure, we detected that co-
exposure to curcumin significantly reduced TCC-induced constitutive endpoints of 
reduced dependence on growth factors (Figure 2.4C1), anchorage-independent growth 
(C2), increased cell proliferation (C3), and ROS elevation (C4), as well as activation of 
the Erk-Nox pathway (C5); these constitutive endpoints were increased in T-10 cells but 
reversed in curcumin-protected, T/C-10 cells.  Accordingly, curcumin was effective in 
the intervention of transient and constitutive endpoints induced by TCC in single and 
105 
 
accumulated exposures, respectively.  Thus, curcumin should be considered for early 
intervention of TCC-induced, cellular pre-malignancy.  
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Legend for Figure 2.4.  Intervention of TCC-induced carcinogenesis by curcumin.  
(A) MCF10A (10A) cells were treated with 0, 0.1, 10, and 20 µmol/L (µM) curcumin for 
72 h.  Quantification of cell viability in these cultures was determined with an MTT assay 
kit.  Relative cell viability was normalized by the value determined in control cells (0 
µM), set as 100%.  (B1 to B4) 10A cells were treated with 200 nmol/L TCC (T) in the 
absence or presence of 1 µmol/L curcumin (C) for 24 h.  (B1) Cell lysates were then 
prepared and analyzed by Western immunoblotting to detect levels of p-Erk1/2, Erk1/2, 
and Nox-1, with β-Actin as a control, and these levels were quantified by densitometry.  
The level of specific phosphorylation of Erk1/2 (p-Erk/Erk) was calculated by 
normalizing the level of p-Erk1/2 with the level of Erk1/2, then the level set in control 
cells as 1 (X, arbitrary unit).  The level of Nox-1 was calculated by normalizing with the 
level of β-Actin and the level set in control cells as 1 (X, arbitrary unit).  (B2) Relative 
ROS levels were measured with CM-H2DCF-DA labeling and normalized by the 
fluorescence intensity determined in control cells, set as 1 (X, arbitrary unit).  (B3) 
Relative cell proliferation was determined and normalized by the value of BrdU detected 
in control cells, set as 100%.  (B4) Relative DNA damage was measured by a comet 
assay and normalized by the value of average tail moment determined in control cells, set 
as 1 (X, arbitrary unit).  (C1 to C4) 10A cells were repeatedly exposed to 200 nmol/L 
TCC (T) in the absence and presence of 1 µmol/L of curcumin (C) for 10 cycles, 
resulting in 10A, C-10, T-10, and T/C-10 cell lines.  To determine levels of cellular 
acquisition of reduced dependence on growth factors (RDGF) (C1) and anchorage-
independent growth (AIG) (C2), cells were maintained in LM medium and seeded in 
soft-agar, respectively.  Cell colonies grown in LM medium and in soft-agar were 
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counted.  (C3) Relative cell proliferation was determined and normalized by the value of 
BrdU detected in parental control cells, set as 100%.  (C4) Relative ROS levels were 
measured with CM-H2DCF-DA labeling and normalized by the fluorescence intensity 
determined in parental control cells, set as 1 (X, arbitrary unit).  (C5) Cell lysates were 
prepared and analyzed by Western immunoblotting to detect levels of p-Erk1/2, Erk1/2, 
and Nox-1, with β-Actin as a control, and these levels were quantified by densitometry.  
The level of specific phosphorylation of Erk1/2 (p-Erk/Erk) was calculated by 
normalizing the level of p-Erk1/2 with the level of Erk1/2, then the level set in parental 
control cells as 1 (X, arbitrary unit).  The level of Nox-1 was calculated by normalizing 
with the level of β-Actin and the level set in control cells as 1 (X, arbitrary unit).).  
Columns, mean of triplicates; bars, SD.  Statistical significance is indicated by ** P < 
0.01, *** P < 0.001.  All results are representative of three independent experiments. 
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Figure 2.4. Intervention of TCC-induced carcinogenesis by curcumin  
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2.5 Conclusion 
 American lifestyles involve wide uses of cleaning agents containing TCC and 
consumption of TCC-contaminated agricultural products.  The role of TCC in increasing 
breast cancer risk has been a concern; however, it has not yet been fully addressed.  Our 
model system revealed, for the first time, that cumulative exposures of human breast cells 
to TCC at physiologically-achievable, nanomolar concentrations induced progressive 
carcinogenesis from a non-cancerous stage to pre-malignant stages in a dose- and 
exposure-dependent manner, suggesting the novel ability of TCC, as a co-carcinogen, to 
induce breast cell pre-malignancy.  Thus, the co-carcinogenic potential of low-dose TCC 
should be seriously considered in epidemiological studies to reveal the significance of 
TCC in the development of sporadic breast cancer.  Using TCC-induced transient and 
constitutive endpoints as targets will enable us to identify additional non-cytotoxic 
preventive agents, such as curcumin, effective in suppressing TCC-induced cellular pre-
malignancy.  However, whether TCC is able to enhance malignancy with other 
carcinogenic agents remains to be clarified.  
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TCC (3,4,4’- trichlorocarbanilide) enhances PhIP-induced breast cell carcinogenesis 
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Research described in this chapter is slightly modified version of an article that will be 
submitted to Molecular Carcinogenesis. 
 TCC (3,4,4’- trichlorocarbanilide) enhances PhIP-induced breast cell 
carcinogenesis by Shilpa Sood, Shambhunath Choudhary, and Hwa-Chain Robert Wang  
In this paper “our” and “we” refers to me and co-authors. My contribution in the 
paper includes the following: 
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing 
experiments (4) understanding the literature and interpretation of the results (5) providing 
comprehensive structure to the paper (6) Preparation of the graphs and figures (7) 
Writing and editing  
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3.1 Abstract 
 More than 85% of breast cancers are sporadic and attributable to long-term 
exposure to environmental carcinogens and co-carcinogens.  Few studies have been 
conducted to study the role of co-carcinogens in potentiating the ability of environmental 
carcinogens known to cause sporadic breast cancer.  We sought to determine the activity 
of triclocarban (TCC), an antimicrobial agent commonly used in household and personal 
care products in enhancing PhIP-induced breast cell carcinogenesis.  We have shown for 
the first time that repeated co-exposures to both TCC and PhIP at bio-achievable 
nanomolar levels effectively induced breast cell carcinogenesis of human breast epithelial 
MCF10A cells from a non-cancerous stage to cancerous state in an in vitro model.  The 
degree of cellular carcinogenesis induced by chronic co-exposures to PhIP and TCC was 
significantly higher than that induced upon chronic exposure to PhIP alone.  Cellular 
carcinogenesis upon co-treatment with TCC and PhIP was characterized by significant 
increases in acquisition of cancer-associated properties of reduced dependence on growth 
factors, anchorage-independent growth, increased cell proliferation, invasion and 
migration as compared to chronic exposure to PhIP alone.  These biological changes were 
accompanied by biochemical and molecular changes, including the activation of the Erk-
Nox pathway, and reactive oxygen species (ROS) elevation which were also significantly 
higher than treatment with PhIP alone.  Moreover, single simultaneous exposure of TCC 
and PhIP also significantly induced transient induction of the Erk-Nox pathway, ROS 
elevation, increased cell proliferation, and DNA damage which were higher as compare 
to PhIP treatment alone.  These constitutively- and transiently-induced endpoints were 
effectively blocked by non-cytotoxic doses of mimosine and ergosterol.  Our data 
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suggests that TCC can act as a co-carcinogen to potentiate PhIP-induced breast cell 
carcinogenesis in in vitro study models.  In addition, mimosine and ergosterol showed a 
lot of potential as novel agents useful in the intervention of sporadic breast cancer as was 
evidenced by suppression of transient and constitutive end points induced upon co-
treatment with TCC and PhIP.    
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3.2 Introduction 
 Breast cancer is the most common type of cancer among women in Europe and 
North America and more than 85% of cases of breast cancer are sporadic in nature [1].  
Exposure to environmental carcinogens is an important factor in the development of 
sporadic breast cancer which is a multistep, multiyear, multipath disease process that 
involves genetic and epigenetic alterations and progression from a non-cancerous stage to 
a precancerous stage and ultimately leading to malignant breast cancer [2,3,4,5].  More 
than 200 chemical carcinogens have been found to be capable of inducing acute 
mammary carcinogenesis at high dosages in vitro and in vivo studies[5,6].  While 
carcinogens induce cellular malignancy, co-carcinogens can either induce a state of cell 
pre-malignancy or are capable to enhancing cellular malignancy.  However, there is 
limited amount of work on the role of co-carcinogens at their physiologically achievable 
doses in enhancing the level of carcinogenesis induced upon chronic exposure to low 
levels of environmental carcinogens, in an event of a co-exposure. 
 Our lab has developed a cellular model that helps to identify potential carcinogens and 
co-carcinogens with the ability to induce breast cell carcinogenesis at their 
physiologically relevant doses [7,8,9,10,11,12,13,14,15]. Our model mimics everyday 
exposure of breast epithelial cells to environmental carcinogens and co-carcinogens at 
physiologically relevant doses by identifying cellular, biochemical and molecular 
transient and constitutive endpoints that are major drivers of initiation and progression of 
breast cell carcinogenesis [11,12,14,15]. Our model also aids in identification of dietary 
preventive agents that can effectively target these transient and constitutive endpoints 
[9,10,11,12,13,14,15]. 
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Triclocarban (TCC), or 3,4,4'-trichlorocarbanilide, is an antibacterial agent commonly 
used in personal care products such as disinfectants, soaps, body washes deodorants, 
detergents, cleansing lotions, wipes etc [16].  TCC is an environmental pollutant and a 
potential co-carcinogen (unpublished results) whose wide spread poses a great risk for 
human health. Recent research has shown that TCC can act as an endocrine disrupter and 
can augment the activities of certain steroid hormones [17, 18].   
2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is heterocyclic amine 
(HCAs) abundantly found in high temperature cooked meats particularly produced during 
grilling and barbequeing procedures [19, 20, 21].  Consumption PhIP via such meats has 
been associated with an enhanced risk of breast neoplasia by epidemiological studies [22; 
23].  Several studies have reported that PhIP is genotoxic to human cells and a 
concentration of PhIP as low as 450 nmol/L induced DNA adduct formation [21, 22, 23, 
24].  Transient exposure of MCF10A cells at nanomolar doses of PhIP caused increased 
cellular proliferation and activated the ERK pathway [25].  Recently, it was reported that 
long-term exposure of breast cells to PhIP at physiologically-achievable, picomolar to 
low nanomolar doses induced carcinogenesis and tumorigenicity [12].  Step wise 
induction of carcinogenesis was accompanied by acquisition of cancer-associated 
properties of reduced dependence on growth factors, anchorage-independent growth, 
increased cellular proliferation, migration, invasion and carcinogenesis in mouse models 
[12]. In addition an upregulated H-Ras gene expression, ERK pathway activation with 
downstream elevation of Nox-1 expression, and elevated reactive oxygen species 
production was noted.  Co-exposure of environmental carcinogens at picomolar to 
nanomolar doses can have an additive effect in the induction of breast cell carcinogenesis 
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[11].  Whether simultaneous co-exposure of breast cells to PhIP and TCC can enhance 
PhIP-induced breast cell carcinogenesis has not been addressed.  Various polyphenolic 
dietary components found to be present in a wide variety of fruits, vegetables, fruits have 
been shown to possess anti-oxidant and antitumor activities such as suppressing 
proliferation, induction of apoptosis. Moreover a lot many more naturally occurring 
component with a potential to inhibit tumor formation need to explored. Ergosterol and 
mimosine are two such promising compounds on the horizon whose anti tumorigenic 
potential needs to evaluated.  
Ergosterol forms a major constituent of fungal cell membranes and stimulates fungal 
growth.  It has been shown to possess antitumor activity attributed to its ability to inhibit 
of angiogenesis in solid tumors [26].  Ergosterol extracted from Japanese edible 
mushroom Hypsizigus marmoreus inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA) 
induced ear inflammation and tumor promotion in carcinogenesis mice models (27).  
Various derivatives of ergosterol viz Ergosterol Peroxide (EP) found in lichens and 
mushrooms possess immunosuppressive anti-viral, anti-inflammatory and anti-tumor 
activities [28, 29, 30, 31].  However, the role of ergosterol and mimosine in sporadic 
breast cancer prevention has not been previously determined. 
Mimosine or leucenol is an alkaloid, β-3-hydroxy-4 pyridone amino acid, initially 
isolated from Mimosa pudica. is also found to occur in some members of genus Mimosa 
and all members of the related genus Leucaena [32].  Mimosine is an iron chelator and 
that inhibits DNA synthesis and mammalian cell proliferation by blocking cell cycle at 
the late G1 phase [33, 34, 35, 36].  It has been shown to inhibit cell proliferation in 
prostate carcinoma cells [37].  In vitro and vivo studies have demonstrated that it has an 
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anticancer effect on human lung cancer cells and xenografts [38, 39].Studies have been 
conducted that gave an evidence of the ability of mimosine to suppress the growth of 
human pancreatic cancer xenografts that were subcutaneously transplanted in nude mice 
and a flow cytometric analysis of the tumor cells yielded a significantly increased sub-G1 
fraction indicating occurrence of apoptosis [40].   
Even though recent experimental data suggests that mimosine and ergosterol have a 
potential anticancer activity, their role in the prevention of progressive cellular 
carcinogenesis especially of breast tissue has not been addressed so far.  So, this work 
was undertaken with the objective of establishing the role of TCC as a co-carcinogen in 
enhancing PhIP-induced breast cell carcinogenesis and to determine if mimosine and 
ergosterol could suppress breast cell carcinogenesis induced by co-exposure to TCC and 
PhIP.  
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3.3 Materials and methods 
3.3.1 Cell Cultures and Reagents 
 MCF10A (American Type Culture Collection [ATCC], Rockville, MD) and 
derived cell lines were maintained in complete (CM) medium (1:1 mixture of DMEM 
and HAM's F12, supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL insulin, 
0.5 µg/mL hydrocortisol, 20 ng/mL epidermal growth factor, and 5% horse serum) [7, 8 , 
9, 10, 11, 12, 13, 14, 15].  Human breast cancer MCF7 and urinary bladder carcinoma 
J82 cells (ATCC) were maintained in DMEM supplemented with 10% heat-inactivated 
fetal bovine serum [lab ref].  All cultures were maintained in medium supplemented with 
100 U/mL penicillin and 100 µg/mL streptomycin in 5% CO2 at 37°C.  Stock aqueous 
solutions of TCC (Sigma-Aldrich, St. Louis, MO), chloromethyl-
dichlorodihydrofluorescein-diacetate (CM-H2DCF-DA) (Invitrogen, Carlsbad, CA), 
U0126 (Cell Signaling, Beverly, MA), and curcumin (MP Biomedicals, Solon, Ohio) 
were prepared in DMSO and diluted in culture medium.  Stock aqueous solutions of N-
acetyl-L-cysteine (NAC) (Alexis, San Diego, CA) were prepared in H2O and diluted in 
culture medium for assays.  
 
3.3.2 Chronic Induction of Cellular Carcinogenesis 
 Twenty-four hours after each subculturing, MCF10A cells were exposed to TCC 
for 48 h, as one cycle of exposure for 10 to 20 cycles; cultures were subcultured every 3 d 
[7, 8 , 9, 10, 11, 12, 13, 14, 15].  After exposures to TCC, cells were assayed to detect 
acquired cancer-associated properties. 
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3.3.3 Reduced dependence on growth factors 
 Five × 103 cells were seeded in 60-mm culture dishes and maintained in low-
mitogen (LM) medium containing reduced total serum and mitogenic additives to 2% of 
the concentration formulated in CM medium.  Cell colonies (≥ 0.5 mm diameter) grown 
in LM medium were counted microscopically [7, 8 , 9, 10, 11, 12, 13, 14, 15]. 
 
3.3.4 Anchorage-independent Growth 
 Five x 103 cells were mixed with soft-agar consisting of 0.4% SeaPlaque agarose 
(Sigma-Aldrich) in a mixture (1:1) of CM medium with 3 d conditioned medium 
prepared from MCF10A cultures, plated on top of the 2% SeaPlaque agarose base layer 
in a 60-mm culture dish, and maintained for 20 d to develop cell clones.  Cell colonies (≥ 
0.1 mm diameter) grown in soft-agar were counted microscopically [7, 8 , 9, 10, 11, 12, 
13, 14, 15]. 
 
3.3.5 Cell Viability Assay 
 A Methyl Thiazolyl Tetrazolium (MTT) assay kit (ATCC) was used to measure 
cell survivability in cultures.  Five x 103 cells were seeded into each well of 96-well 
culture plates for 24 h.  After indicated treatments, cells were incubated with MTT 
Reagent for 4 h, followed by incubation with detergent reagent for 24 h.  Reduced MTT 
reagent in cultures was quantified with an ELISA reader (Bio-Tek, Winooski, VT) [41, 
42]. 
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3.3.6 Cell Proliferation 
 Cell proliferation was determined by of 5-bromo-2’-deoxyuridine (BrdU) 
incorporation into cellular DNA using the BrdU cell proliferation ELISA kit (Roche, 
Indianapolis, IN).  Five x 103 cells were seeded into each well of 96-well culture plates 
for 24 h.  After treatment, cells were labeled with BrdU for 12 h, fixed, incubated with 
peroxidase-conjugated BrdU-specific antibodies, and stained with peroxidase substrate.  
Quantification of BrdU-labeled cells was determined with an ELISA reader (Bio-Tek) 
[41, 42, 43]. 
 
3.3.7 Intracellular ROS Measurement 
 As performed previously [11,12,44], cells were incubated with 5 µmol/L CM-
H2DCF-DA for 1 h to detect ROS level by flow cytometry; the mean fluorescence 
intensity of DCF was quantified using Multicycle software (Phoenix).  
 
3.3.8 In vitro cell invasion and migration 
The cell invasion assay was performed using 24-well Transwell insert-chambers with a 
polycarbonate filter with a pore size of 8.0 µm (Costar, Corning, NY).  Two x 104 cells in 
serum-free medium were seeded on top of a Matrigel-coated filter (BD Biosciences) in 
each insert-chamber.  Then, insert-chambers were placed into wells on top of culture 
medium containing 10% horse serum as a chemoattractant.  The migration assay was 
performed using 24-well Transwell insert-chambers with a polycarbonate filter without 
Matrigel.  The invasive or migratory ability of cells was determined by the number of 
cells translocated to the lower side of filters [45, 11, 12]. 
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3.3.9 DNA Damage 
 DNA damage was measured by a comet assay [11, 12, 46].  Cells were mixed 
with 1% low-melting agarose and placed on agarose-coated slides.  Slides were then 
immersed in lysis solution (1.2 mol/L NaCl, 100 mmol/L Na2EDTA, 1% Triton X-100, 
and 0.3 nmol/L NaOH, pH 13) at 25°C for 1 h and rinsed three times with alkaline buffer 
(2 mmol/L Na2EDTA and 300 mmol/L NaOH) for 20 min each.  After electrophoresis in 
the same alkaline buffer at 20V for 30 min, slides were stained with 2.5 µg/mL of 
propidium iodide for 20 min and examined with a Zeiss fluorescence microscope 
(Thornwood, NY) equipped with an excitation filter of 546 nm and barrier filter of 590 
nm.  Fifty nuclei per slide were scored for tail moment (% of DNA in the tail × tail 
length) using CometScore software (Tritek, USA).  
 
3.3.10 Western Immunoblotting 
 Equal amounts of cellular proteins were resolved by electrophoresis in 10% SDS-
polyacrylamide gels and transferred to nitrocellulose filters for immunoblotting [47, 48, 
49].  Specific antibodies were used to detect H-Ras, phosphorylated Mek (p-Mek), Mek, 
phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, and β-Actin (Santa Cruz 
Biotechnology, Santa Cruz, CA).  Antigen-antibody complexes on filters were detected 
by the Supersignal chemiluminescence kit (Pierce, Rockford, IL). 
 
3.3.11 Statistical Analysis 
 The Student t test was used to analyze statistical significance, indicated by * P < 
0.05, ** P < 0.01, *** P < 0.001; a P value of ≤ 0.05 was considered significant. 
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3.4 Results  
3.4.1 TCC-enances PhIP-induced breast cell carcinogenesis 
Normal cells require growth factors for their survival and growth. In the absence of 
growth factors cells undergo apoptosis [50, 51].  Normal cells also require cell adhesion 
to extracellular matrix for survival and in its absence they die by a process of anoikis 
[50].  Cells that progressively acquire abilities to grow under the limiting conditions of 
reduced amounts of growth factors and absence of adhesion to extracellular matrix are 
thought to have acquired tumorigenic potential.  Moreover, anchorage–independent 
growth and reduced dependence on growth factors are two important cancer-associated 
properties and have been used to measure progressive carcinogenesis of non-cancerous 
cells in response to exposure to environmental carcinogens [7, 8, 9, 10, 11, 12].  We used 
these two cancer-associated properties as long-term targeted endpoints to determine 
whether co-exposure of TCC and PhIP enhanced PhIP-induced breast cell carcinogenesis.  
We repeatedly exposed MCF10A cells to either individual or combined TCC or PhIP 
treatments at their physiologically achievable doses of 200 nM and 10 nM respectively 
for 10 and 20 cycles (Fig 3.1).  We detected that individual and combined treatments to 
TCC and PhIP resulted in significant increase in number of surviving cell clones under 
the conditions of reduced dependence of growth factors and anchorage independence 
with increasing exposures (Fig 3.1A1-A2).  Our results validated the previous published 
data that PhIP at physiologically achievable doses of 10 nM induced breast cell 
carcinogenesis in MCF 10 cells.    
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Legend for Figure 3.1.  TCC enhances PhIP-induced breast cell carcinogenesis 
 MCF10A cells were repeatedly exposed to individual (T, P) or combined TCC and PhIP 
(TP) at 200 nmol/L and 10 nM/L respectively for 10, and 20 cycles.  MCF10A cells were 
stably transfected to ectopically express oncogenic H-Ras, resulting in the MCF10A-Ras 
cell line (Ras).  (A1) To determine acquisition of the cancer-associated property of 
reduced dependence on growth factors (RDGF), cells were maintained in LM medium.  
(A2) To determine acquisition of the cancer-associated property of anchorage-
independent growth (AIG), cells were seeded in soft-agar.  Cell colonies grown in LM 
medium and soft-agar were counted microscopically.  (B1) Relative ROS levels were 
measured with CM-H2DCF-DA labeling and normalized by the fluorescence intensity 
determined in control (10A) cells, set as 1 (X, arbitrary unit).  (B2) Relative cell 
proliferation was determined and normalized by the value of BrdU detected in MCF10A 
cells, set as 100%.  (B3) Migratory and (B4) invasive activities were determined by 
counting the numbers of cells translocated through a polycarbonate filter without or with 
coated Matrigel, respectively, in 10 arbitrary visual fields.  Columns, mean of triplicates; 
bars, standard deviation.  The Student’s t test was used to analyze statistical significance, 
indicated by * P < 0.05, ** P < 0.01, *** P < 0.001.
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Figure 3.1.  TCC enhances PhIP-induced breast cell carcinogenesis.  
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More significantly, accumulated exposures to combined treatments additively increased 
number of cell clones formed under the conditions of reduced dependence of growth 
factors and anchorage–independent growth as compared to those formed after cumulative 
exposures to PhIP or TCC alone (Fig 3.1A1-A2).   
Since exposures of MCF10A cells to PhIP after 20 cycles resulted in fifty percent of mice 
forming tumors in our earlier studies [12], we used twenty cycle exposed cells for our 
further studies to determine the potential of TCC to confer additional carcinogenic 
abilities to PhIP cells.  We named MCF10A cells treated either individually or together 
with TCC and PhIP as T20, P20 and TP20 cells respectively.  We used MCF10A-Ras 
cells, which are MCF10A cells with ectopic expression of oncogenic H-Ras, as positive 
control for our studies.  Our previous data had shown that P20 cells produced ROS, 
proliferated at a higher degree and had higher abilities of invasion and migration as 
compared to the MCF10A cells.  We wanted to see if twenty cycles of co-exposure to 
TCC and PhIP could enhance ROS production, cell proliferation, migration and invasion 
potential of P20 cells.  As shown in Figure 3.1B1-B4, TP20 cells produced higher 
amounts of ROS, proliferated at higher degrees and had significantly higher abilities of 
invasion and migration as compared to P20 cells but either comparable or significantly 
less degrees as compared to MCF10A-Ras cells that served as a positive control.  Hence, 
our results showed that cumulative exposures to TCC could enhance breast cell 
carcinogenesis induced by PhIP. 
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3.4.2 Role of ERK pathway in TP-induced cancer associated properties  
P20 cells have been shown to have higher expression of Ras, p-ERK, p-MEK and Nox-1 
levels [12] and activation of Ras-Erk Nox pathway drove the progressive carcinogensis of 
MCF10A cells from nonmalignant to premalignant to a malignant stage.  We wanted to 
see if co-exposure to TCC and PhIP would result in a higher activation of Ras ERK Nox 
pathway. Twenty cycles of co-exposure to TCC and PhIP didn’t induce higher protein 
levels of Ras than P20 cells (Fig 3.2A).  However, TP20 cells had a higher expression of 
p-Mek, p-Erk, Nox-1 protein as compared to P20 cells.  So, TP20 cells had a higher 
degree of activated Mek-Erk-Nox pathway as compared to P20 cells (Fig 3.2A).  To 
further validate the involvement of ERK pathway in inducing cancer associated 
properties in TP20 cells, we found that inhibiting ERK pathway with U0 not only 
blocked the activation of ERK pathway but also repressed elevated Nox-1 protein levels 
(Fig 3.2B).  U0 also blocked ROS and cell proliferation in TP20 cells (Fig 3.2B2-B3).  
These results prove that ERK pathway played an important role in the enhanced 
carcinogenic potential of TP20 cells as compared to P20 cells.   
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Legend for Figure 3.2.  Role of ERK Pathway in modulation of TP-induced cancer-
associated properties.  MCF10A cells were repeatedly exposed to individual (T, P) or 
combined TCC and PhIP (TP) at 200 nmol/L and 10 nM/L respectively for 20 cycles.  
MCF10A cells were stably transfected to ectopically express oncogenic H-Ras, resulting 
in the MCF10A-Ras cell line (Ras).  (A) Lysates from cells exposed to TCC or PhIP 
individually or together for 20 cycles were prepared and analyzed by immunoblotting 
using specific antibodies to detect levels of phosphorylated Mek1/2 (p-Mek1/2), Mek1/2, 
phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, with β-Actin as a control.  The level of 
specific phosphorylation of Mek1/2 (p-Mek1/2) was calculated by normalizing the level 
of p-Mek1/2 with the level of Mek1/2, then the level set in MCF10A cells as 1 (X, 
arbitrary unit).  The level of specific phosphorylation of Erk1/2 (p-Erk1/2) was calculated 
by normalizing the level of p-Erk1/2 with the level of Erk1/2, then the level set in 
MCF10A cells as 1 (X, arbitrary unit).  The levels of Nox-1 were calculated by 
normalizing with the level of β-Actin, the level set in MCF10A cells as 1 (X, arbitrary 
unit).  All results are representative of three independent experiments.  (B1-B3) MCF10A 
andTP20 cells were treated without or with 10 µM/L U0126 (U) for 48 h.  (B1) Cell 
lysates were prepared and analyzed by immunoblotting to detect levels of phosphorylated 
Erk1/2 (p-Erk1/2), Erk1/2, and Nox-1, with β-Actin as a control, and these levels were 
quantified by densitometry.  The levels of Nox-1 were calculated by normalizing with the 
level of β-Actin and the level set in untreated control cells as 1 (X, arbitrary unit).  The 
levels of specific phosphorylation of Erk1/2 (p-Erk1/2) were calculated by normalizing 
the levels of p-Erk1/2 with the levels of Erk1/2 , then the level set in control cells as 1 (X, 
arbitrary unit).  (B2) ROS levels were measured with CM-H2DCF-DA labeling; relative 
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level of ROS, as fold induction (X, arbitrary unit), was normalized by the level 
determined in MCF10A cells, set as 1.  (B3) Cell proliferation was determined; relative 
cell growth rate was normalized by the value of BrdU detected in MCF10A cells, set as 
100%.  Columns, mean of triplicates; bars, standard deviation.  The Student’s t test was 
used to analyze statistical significance, indicated by * P < 0.05, ** P < 0.01, *** P < 
0.001.  All results are representative of three independent experiments.  
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Figure 3.2 Role of ERK Pathway in modulation of TP-induced cancer-associated 
properties  
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3.4.3 TCC enhances PhIP-induced transient endpoints 
To investigate the mechanisms underlying chronic carcinogenesis induced by 
simultaneous treatments with PhIP and TCC in MCF10A cells, and to determine if short 
term treatment with TCC also enhanced, PhIP-induced transient endpoints in MCF10A 
cells and thus contributed towards enhancement of PhIP-induced cellular carcinogenesis 
by TCC in TP20 cells, we subjected MCF10A cells to single exposure of TCC and PhIP 
at their bio-achievable doses.  First of all, we wanted to determine the time of maximum 
activation of ERK pathway after co-treatment with TCC and PhIP.  PhIP has been shown 
to induce maximum p-ERK levels in 24 hours.  As can be seen in Figure 3.3A, combined 
treatment of PhIP and TCC induced maximal levels of p-ERK after 24 hours of the co-
treatment.  We chose this time interval for our further experiments.  We have also shown 
earlier that 24 h of PhIP treatment leads to a transient upregulation of HRas protein and 
also induced downstream ERK-Nox pathway [12].  We wanted to investigate whether co-
exposure of TCC and PhIP would elevate the protein expression of HRas and activation 
of downstream ERK-Nox pathway.  As we can see in Figure 3.3B, short-term treatment 
of MCF10A cells with PhIP and TCC didn’t cause any changes in HRas expression levels 
induced by PhIP.  However, we found that co-treatment of TCC and PhIP were able to 
additively enhance protein expression of phosphorylated Erk1/2 levels and Nox-1 levels 
induced by PhIP.  Moreover, upon blocking ERK pathway by use of inhibitors like U0, 
ERK-Nox activation was blocked.  In our previous study, we had shown that PhIP-
induced transient activation of ERK pathway leading to ROS elevation which increased 
cell proliferation in MCF10A cells [12].  
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Legend for Figure 3.3.  Short-term targeted endpoints: TCC enhances ROS 
elevation, ERK pathway, cell proliferation, and DNA damage transiently induced by 
short term exposure to PhIP.  (A) MCF10A (10A) cells were coexposed to 200 nmol/L 
TCC (T) and 10 nM PhIP (P) for the indicated periods.  (B) MCF10A cells were treated 
either individually (T, P) or together (TP) with 200 nmol/L TCC (T) and 10 nM PhIP (P) 
for 24 h.  (C) MCF10A cells were treated either individually (T, P) or together (TP) with 
200 nmol/L TCC (T) and 10 nM PhIP (P) for 24 h in the absence or presence 10 µmol/L 
U0126 (U).  (A-C) Cell lysates were prepared and analyzed by Western immunoblotting 
to detect levels of p-Erk1/2, Erk1/2, and Nox-1, with β-Actin as a control, and these 
levels were quantified by densitometry.  The levels of Nox-1 were calculated by 
normalizing with the level of β-Actin and the level set in untreated control cells as 1 (X, 
arbitrary unit).  The levels of specific phosphorylation of Erk1/2 (p-Erk1/2) were 
calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the level 
set in control cells as 1 (X, arbitrary unit).  (D1-D3) MCF10A (10A) cells were treated 
either individually (T, P) or together (TP) with 200 nmol/L TCC (T) and 10 nM PhIP (P) 
in the absence or presence of 10 µmol/L U0126 (U), 5 mmol/L NAC (N) for 24 h.  (D1) 
Relative ROS levels were measured with CM-H2DCF-DA labeling and normalized by the 
fluorescence intensity determined in untreated cells, set as 1 (X, arbitrary unit).  (D2) 
Relative cell proliferation was determined and normalized by the value of BrdU detected 
in untreated cells, set as 100%.  (D3) Relative DNA damage was measured by a comet 
assay and normalized by the value of average tail moment determined in untreated 
counterpart cells, set as 1 (X, arbitrary unit).  (E1) To determine reduced dependence on 
growth factors (RDGF) cells were maintained in LM medium.  (E2) To determine 
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anchorage-independent growth (AIG), cells were seeded in soft-agar.  Representative 
images of DNA damage in the comet assay are shown.  (E1-E2)  MCF10A (10A) cells 
were repeatedly exposed to 200 nM TCC and 10 nmol/L PhIP in the absence and 
presence of 2 µmol/L U0126 (U), for 5 cycles, resulting in 10A, TP5, TP5/U5 cell lines 
respectively.  Columns, mean of triplicates; bars, standard deviation.  The Student’s t test 
was used to analyze statistical significance, indicated by * P < 0.05, ** P < 0.01, *** P < 
0.001.  All results are representative of three independent experiments.  
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Figure 3.3.  Short-term targeted endpoints: TCC enhances ROS elevation, ERK 
pathway, cell proliferation, and DNA damage transiently induced by short term 
exposure to PhIP  
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Increased ROS production was responsible for inducing DNA damage.  We wanted to 
determine whether TCC can potentiate PhIP’s ability to cause ROS production, cell 
proliferation and induce DNA damage after transient co-exposure with TCC and PhIP.  
As shown in figure 3.3D1-3.3D3, TCC significantly enhanced PhIP-induced ROS 
production, cell proliferation and DNA damage which was suppressed by blocking ERK 
Pathway and ROS production using U0 and NAC respectively.  These results indicate 
that ERK pathway and ROS played important role in TCC’s ability to enhance PhIP-
induced transient targeted endpoints.  
This proves that TCC increased transient induction of the Erk-Nox pathway to cause 
ROS elevation and cellular proliferation, induced by PhIP treatment with each exposure 
cycle.  Hence, cumulative co-exposures to TCC and PhIP increased the accumulation of 
DNA damage caused by PhIP treatment alone leading to an enhanced level of progressive 
carcinogenesis in PhIP treated cells.   
To further validate the role of ERK pathway in TP-induced carcinogenesis, we treated 
MCF10A cells with TCC and PhIP in the presence and absence of U0(U) for five 
consecutive exposure cycles to generate 10A, U5, TP5 and TP/U5 cells.  We found that 
U0 was able to repress number of colonies formed under the conditions of reduced 
dependence of growth factors and anchorage-independent growth in MCF10A cells co-
treated with TCC and PhIP for 5 cycles(Fig 3.3E).  These data show that co-exposure to 
TCC and PhIP potentiated the degree of transient as well as constitutive endpoints 
induced by treatment with PhIP alone and that activated ERK pathway played an 
important role in potentiating initiation and progression of PhIP-induced carcinogenesis 
by co-treatment with TCC and PhIP. 
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3.4.4 TCC enhanced PhIP-induced transient endpoints in breast carcinoma and 
bladder cancer cells. 
To investigate if TCC’s ability to enhance the degree of PhIP-induced transient endpoints 
was not limited to MCF10A cells, we subjected breast carcinoma MCF7 cells and bladder 
cancer J82 cells to a single exposure of physiologically achievable doses of TCC and 
PhIP.  Co-exposure to TCC and PhIP was able to induce Erk-Nox pathway (Fig3 4A) 
leading to ROS elevation (Fig 3.4B) and DNA damage (Fig 3.4C) in MCF7 and J82 cells.  
More importantly, combined exposure significantly enhanced the ability of PhIP to 
activate ERK Nox pathway, ROS production and cell proliferation.  This shows that co-
treatment with TCC has the similar effect of potentiating PhIP-induced activation of the 
ERK Pathway in other types of cell lines.  These results also show that TCC induced 
transient endpoints not only in non-cancerous, ER-negative MCF10A cells but also in the 
ER-positive cancerous MCF7 cells.  Therefore, TCC –induced potentiation of cellular 
carcinogenesis due to PhIP exposure is independent of ER- status of the cells. 
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Legend for Figure 3.4.  TCC enhances PhIP-induced ERK Pathway activation, ROS 
elevation, and DNA damage in breast carcinoma and bladder cancer cells.  (A-C) 
MCF7 and J82 cells were exposed to individual (T, P) or combined TCC and PhIP (TP) 
at 200 nmol/L and 10 nM/L respectively for 24 h.  (A) Cell lysates were prepared and 
analyzed by immunoblotting to detect levels of p-Erk1/2, Erk1/2, and Nox-1, with β-
Actin as a control, and these levels were quantified by densitometry.  The level of 
specific phosphorylation of Erk1/2 (p-Erk1/2) was calculated by normalizing the level of 
p-Erk1/2 with the level of Erk1/2, then the level set in control cells as 1 (X, arbitrary 
unit).  The level of Nox-1 (Nox/Actin) was calculated by normalizing with the level of β-
Actin and the level set in control cells as 1 (X, arbitrary unit).  (B) Relative ROS levels 
were measured with CM-H2DCF-DA labeling and normalized by the fluorescence 
intensity determined in control cells, set as 1 (X, arbitrary unit).  (C) Relative DNA 
damage was measured by a comet assay and normalized by the value of average tail 
moment determined in control cells, set as 1 (X, arbitrary unit).  Columns, mean of 
triplicates; bars, SD.  Statistical significance is indicated by * P < 0.05, ** P < 0.01, *** 
P < 0.001.  All results are representative of three independent experiments.
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Figure 3. TCC enhances PhIP-induced ERK Pathway activation, ROS elevation, 
and DNA damage in breast carcinoma and bladder cancer cells.  
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3.4.5 Mimosine and ergosterol suppression of TP-induced short-term targeted 
endpoints 
To first determine the non-cytotoxic doses of ergosterol and mimosine, we studied 
cytotoxicity of these two compounds in MCF10A cells.  As shown in the figure 3.5A1 
and3 5A2, treatment of MCF10A cells with either ergosterol or mimosine at 
concentrations of 100 nM or more significantly reduced cell viability.  However, 
treatment with neither mimosine nor ergosterol at 10 nM induced any detectable 
reduction in cell viability.  So, we used 10 nM ergosterol or mimosine in our subsequent 
studies.  To study whether ergosterol or mimosine could block combined TCC and PhIP-
induced initiation of carcinogenesis, we exposed MCF10A cells to either DMSO or TCC 
and PhIP together in the presence and absence of these two compounds for 24 h.  As 
shown (Fig3.5B1-B4), both ergosterol and mimosine were able to suppress simultaneous 
TCC and PhIP treatment induced transient phosphorylation of Erk1/2, induction of Nox-
1, ROS elevation, increased cell proliferation, and DNA damage.  These results indicate 
that ergosterol and mimosine at non cytotoxic concentrations could block combined TCC 
and PhIP-induced transient endpoints of breast cell carcinogenesis. 
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Legend for Figure 3.5.  Mimosine and ergosterol suppression of TP-induced short 
term targeted endpoints.  (A1) MCF10A cells were treated with 0, 100 pM, 1 nM, 10 
nM, 100 nM, 1 µM, 10 µM and 20 µmol/L ergosterol (E) for 72 h.  Quantification of cell 
viability in these cultures was done with an MTT assay kit.  Relative cell viability was 
normalized by the value determined in untreated cells, set as 100%.  Columns, mean of 
triplicates; bars, SD.  (A2) MCF10A (10A) cells were treated with 0, 100 pM, 1 nM, 10 
nM, 100 nM, 1 µM, 10 µM and 20 µmol/L mimosine (M) for 72 h.  Cell viability in these 
cultures was determined with an MTT assay kit.  Relative cell viability was normalized 
by the value determined in untreated cells, set as 100%.  Columns, mean of triplicates; 
bars, SD.  (B1-B4) MCF10A (10A) cells were treated with 200 nmol/L TCC (T) and 10 
nmol/L PhIP (P) together (TP) in the absence or presence of 10 nmol/L ergosterol (E) or 
10 nmol/L mimosine (M) for 24 h.  (B1) Cell lysates were then prepared and analyzed by 
Western immunoblotting to detect levels of specific phosphorylation of Erk1/2 (p-
Erk1/2), Erk1/2, and Nox-1, with β-Actin as a control, and these levels were quantified 
by densitometry.  The level of Nox-1 were calculated by normalizing with the level of β-
Actin and the level set in control MCF10A cells as 1 (X, arbitrary unit).  The level of 
specific phosphorylation of Erk1/2 (p-Erk1/2) was calculated by normalizing the level of 
p-Erk1/2 with the level of Erk1/2, then the level set in MCF10A cells as 1 (X, arbitrary 
unit).  (B2) Relative ROS levels were measured with CM-H2DCF-DA labeling and 
normalized by the fluorescence intensity determined in MCF10A cells, set as 1 (X, 
arbitrary unit).  (B3) Relative cell proliferation was determined and normalized by the 
value of BrdU detected in MCF10A cells, set as 100%.  (B4) Relative DNA damage was 
measured by a comet assay and normalized by the value of average tail moment 
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determined in untreated counterpart cells, set as 1 (X, arbitrary unit).  Columns, mean of 
triplicates; bars, standard deviation.  The Student’s t test was used to analyze statistical 
significance, indicated by ** P < 0.01, *** P < 0.001.  All results are representative of 
three independent experiments.  
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Figure 3.5.  Mimosine and ergosterol suppression of TP-induced short term targeted 
endpoints  
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3.4.6 Intervention of TP-induced chronic cell carcinogenesis by mimosine and 
ergosterol 
To determine whether mimosine and ergosterol could suppress chronic cellular 
carcinogenesis induced by co-exposure to TCC and PhIP, MCF10A cells were exposed to 
either DMSO or PhIP and TCC together, in the absence and presence of ergosterol and 
mimosine for 10 cycles to yield 10A, E10, M10, TP10, TP/E10 and TP/M10 cells 
respectively.  Cells co-exposed to TCC and PhIP after 10 cycles exhibited higher degrees 
of cancer-associated properties of anchorage-independent growth and reduced 
dependence on growth factors which were significantly reduced by mimosine and 
ergosterol co-treatment (Figure 3.6A and 3.6B).  Moreover, mimosine and ergosterol 
reduced combined PhIP and TCC-induced constitutively increased ROS production and 
cell proliferation in TP10 cells (Figure 3.6C-3.6D).  We also found that chronically 
induced Erk-Nox pathway in TP10 cells was suppressed by both ergosterol and mimosine 
(Figure 3.6E).  These results indicate that mimosine and ergosterol were able to block 
TCC and PhIP-induced chronic cellular carcinogenesis.  So, they are new promising 
agents that can be useful in the prevention of sporadic breast cancer.  
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Legend for Figure 3.6.  Intervention of TP-induced chronic breast cell 
carcinogenesis by ergosterol and mimosine.  (A-E) MCF10A (10A) cultures were 
repeatedly exposed to either DMSO or 200 nmol/L TCC and 10 nmol/L PhIP together 
(TP) in the absence and presence of 10nM/L ergosterol (E)or 10 nM/L mimosine (M) for 
10 cycles, resulting in 10A, E10, M10, TP10, TP/E10 and TP/M10 cell lines, 
respectively.  To determine reduced dependence on growth factors (RDGF) (A) and 
anchorage-independent growth (AIG) (B), cells were maintained in LM medium and 
seeded in soft-agar respectively.  Cell colonies grown in LM medium and soft-agar were 
counted.  (C) Relative ROS levels were measured with CM-H2DCF-DA labeling and 
normalized by the fluorescence intensity determined in MCF10A cells, set as 1 (X, 
arbitrary unit).  (D) Relative cell proliferation was determined and normalized by the 
value of BrdU detected in MCF10A cells, set as 100%.  (E) Cell lysates were prepared 
and analyzed by Western immunoblotting to detect levels of Erk1/2 phosphorylation (p-
Erk1/2), Erk1/2, and Nox-1, with β-Actin as a control, and these levels were quantified 
by densitometry.  The level of Nox-1 were calculated by normalizing with the level of β-
Actin and the level set in control MCF10A cells as 1 (X, arbitrary unit).  The level of 
specific phosphorylation of Erk1/2 (p-Erk1/2) was calculated by normalizing the level of 
p-Erk1/2 with the level of Erk1/2, then the level set in MCF10A cells as 1 (X, arbitrary 
unit).  Columns, mean of triplicates; bars, standard deviation.  The Student’s t test was 
used to analyze statistical significance, indicated by ** P < 0.01, *** P < 0.001.  All 
results are representative of three independent experiments.  
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Figure 3.6.  Intervention of TP-induced chronic breast cellular carcinogenesis by 
ergosterol and mimosine.  
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3.5 Discussion 
Human body is constantly exposed to different kinds of pollutants on a day to day basis 
through a variety of ways for example, through diet and use of personal care products.  
Exposure to some of the known carcinogens like consumption of PhIP through over 
cooked meat has been shown to have the potential to cause breast carcinogenesis.  Many 
of the constituents used in the manufacture of personal care products like TCC are under 
the scanner for their capability to cause breast cancer or act as a co-carcinogen whwereby 
they enhance the potential of other carcinogens like PhIP in causing breast cancer.  In this 
study we wanted to determine whether TCC has the ability to enhance the initiation and 
progression of malignant breast cell carcinogenesis caused by PhIP.  We have developed 
a model system in our lab which has shown a remarkable ability to detect induction and 
progression of chronic breast cell carcinogenesis by repeated exposures to 
physiologically relevant doses of environmental carcinogens like NNK, B[a]P and PhIP 
[11,12].  In contrast to other cell systems that utilize high dose regimens in the 
micromolar to millimolar ranges to acutely induce carcinogenesis, our model system 
relies on bio-achievable nanomolar to picomolar concentrations of carcinogens to study 
progressive cellular carcinogenesis [8,9,10,11,12].  In addition, our model system has 
shown the potential to identify naturally occurring agents that are easily consumed 
through daily diet at their non-cytotoxic doses, which have the capability to intervene 
breast cell carcinogenesis induced by repeated exposures to environmental agents.  In the 
present study, we utilized our unique model system to identify the roles of mimosine and 
ergosterol in suppressing chronic breast cellular carcinogenesis induced by co-treatment 
of TCC and PhIP.  Our model system also revealed the mechanisms behind the ability of 
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mimosine and ergosterol to target the process of chronic carcinogenesis induced by co-
exposure to TCC and PhIP at biological, biochemical and molecular levels.  Hence our 
model system will help in identification of additional carcinogens, co-carcinogens and 
preventive agents capable of induction and intervention of sporadic breast cancer. 
Using certain biological, biochemical and molecular transient and constitutive targeted 
endpoints, we determined that TCC potentiated the ability of PhIP to initiate and progress 
the process of cellular carcinogenesis in MCF10A cells.  MCF10A cells co-exposed to 
PhIP and TCC (TP20) acquired higher levels of cancer-associated properties, ROS 
generation potential, proliferation, migration and invasion capabilities as compared to 
P20 cells and these properties were comparable to that of MCF10A-Ras cells.  Co-
treatment with TCC and PhIP for 20 cycles did not increase Ras protein expression in 
TP20 cells when compared to Ras expression level in P20 cells.  However, 
phosphorylated Mek, phosphorylated Erk and Nox-1 levels were enhanced leading to 
significantly higher ROS production and cell proliferation.  Also, co-exposure of PhIP 
and TCC was able to induce ROS in a Ras-independent manner.  Therefore, ROS 
generated via a Ras-independent manner was responsible for enhancing PhIP-induced 
activation of ERK pathway, ROS production, cell proliferation and DNA damage in cells 
simultaneously treated with TCC and PhIP.  However, the mechanism behind Ras-
independent induction of ROS that contributed towards enhancement of TP-induced 
carcinogenesis remains to be studied.  Moreover, our study has shown that mimosine and 
ergosterol were able to block breast cell carcinogenesis induced by simultaneous 
treatment with PhIP and TCC.  This study reveals for the first time the role of TCC as a 
co-carcinogen in enhancing PhIP-induced breast cell carcinogenesis in an in-vitro model.
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Chapter 4  
 
  
160 
 
4.1 Summary 
An overwhelming majority of breast cancers are sporadic in nature attributable to chronic 
exposure to environmental factors, through a multi-year, multi-step, and multi-path 
process involving genetic and epigenetic alterations leading to progressive development 
from a non cancerous stage to premalignant and ultimately malignant breast cancer.  
Most current studies for induction of carcinogenesis involve use of high doses of 
carcinogens in their micromolar to millimolar doses to acutely induce cancers.  However, 
this does not truly reflect the physiological process of carcinogenesis which involves low 
dose exposure to carcinogens.  In the present study, I used a model that mirrors the actual 
carcinogenesis process by using a low dose exposure strategy in which normal breast 
epithelial MCFA cells are exposed to physiologically achievable doses of co-carcinogens 
and carcinogens over multiple passages (cycles). The experimental scheme which I used 
for my work is shown in Figure 4.1.  MCF10A cells were exposed to either TCC, PhIP 
alone or together, in the absence or presence of preventive agents like curcumin, 
ergosterol or mimosine for 10-20 cycles.  After the multiple exposures to either TCC or 
PhIP individually or together, the cells were analysed for acquisition of cancer associated 
properties of reduced dependence on growth factors and anchorage independent growth. 
  
  
 
 
Figure 4.1 Experimental Scheme of induction of premalignant breast cellular 
carciniogenesis and intervention
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 Cells were also evaluated for acquisition of cetain molecular endpoints.as shown in 
Figure 4.2.  These endpoints included activation of the Erk pathway with increased 
phospho-Erk and down stream Nox-1 protein levels, increased cell proliferation and ROS 
production.  My hypothesis was that long-term exposure to TCC can induce breast cell 
carcinogenesis and co-exposure to TCC and PhIP can enhance PhIP-induced breast cell 
carcinogenesis which can be prevented using curcumin, ergosterol and mimosine.  
First of all, I wanted to determine if chronic exposure to physiologically achievable doses 
of TCC would cause breast epithelial cells to acquire the cancer-associated properties and 
also wanted to evaluate the potential of curcumin in the intervention of TCC-induced 
breast cell carcinogenesis.  Working towards these objectives, I treated MCF10A cells 
with TCC for 10-20 cycles with three different doses of TCC including the bioachievable 
dose of 200 nM.  It was observed that there was induction of acquisition of cancer-
associated properties of reduced dependence on growth factors and anchorage–
independent growth in cells treated with TCC in a dose and exposure dependent manner 
with activation of Erk-Nox pathway.  These changes were constitutively induced in 
response to chronic TCC treatment.  Even though physiologically achievable 200 nM was 
found to induce significant premalignant breast cell carcinogenesis related changes in 
MCF10A cells after 20 cycle of exposure, these T20 cells were not found to be 
tumorigenic in nude mice.  Single exposure of TCC to MCF10A cells was also found to 
induce transient endpoints of Erk pathway activation, enhanced ROS production, cellular 
proliferation and DNA damge.  Inhibiting Erk pathway and ROS suppressed transient as 
well as constitutive endpoints induced by TCC.  Curcumin at noncytotoxic dose of 1uM 
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was tested for its ability to impede TCC-induced transient and constitutive endpoints in 
MCF10A cells.  
164 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.2 Targeted Molecular endpoints in breast cell carcinogenesis   
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It was observed that curcumin suppressed TCC-induced cancer associated properties of 
reduced dependence on growth factors, anchorage independent growth and also 
suppressed constitutive and transiently induced cell proliferation and ROS production, 
erk pathway activation.  Co-treatment with curcumin also caused significant reduction in 
TCC induced DNA damage in MCF 10A cells.   
To further study the potential of TCC to act as a co-carcinogen, I sought to determine if 
TCC could enhance PhIP-induced breast cell carcinogenesis and also wanted to 
determine whether mimosine and ergosterol could block breast cell carcinogenesis 
induced by co-treatment with TCC and PhIP.  MCF10A cells were treated with 
bioachievable doses of PhIP and TCC either individually or together for 10 and 20 
cycles.  Validating previous results, I found that cells treated with either PhIP or TCC 
induced formation of significantly higher number of cell clones when compared to the 
untreated control cells.  More importantly however, co-treating cells with PhIP and TCC 
significantly increased the level of cancer-associated properties acquired by these cells 
when compared to the cells treated with PhIP or TCC alone.  Similarly, simultaneous 
TCC and PhIP treatment for twenty cycles was found to enhance migration, invasion, cell 
proliferation and ROS generation capabilities of cells treated for 20 cycles with PhIP 
alone.  Chronic TCC and PhIP co-treatment was able to activate Erk-Nox pathway to a 
higher level as compared to cells treated with PhIP alone.  These results indicated that 
TCC was able to significantly enhance breast cell carcinogenesis induced by PhIP alone.  
Erk pathway was found to play an important role in chronic breast cell carcinogenesis 
induced by co-exposure to TCC and PhIP since its inhibition blocked breast cell 
carcinogenesis induced by treatment with TCC and PhIP.  To find the underlying 
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mechanism of breast cell carcinogenesis induced by the co-exposure to TCC and PhIP, 
cells were treated with TCC and PhIP for 24 h to see if transient end points of 
carcinogenesis were induced.  The results indicated that co-treatment caused activation of 
Erk-Nox pathway in MCF10A cells to a higher level as compared to that induced by 
individual treatment with PhIP.  In the similar manner, co-treatmet with both the 
compounds also induced significanty higher levels of ROS, cell proliferation and DNA 
damage as compared to cells treated with PhIP alone.  These results proved that co-
treatment with TCC and PhIP significantly potentiated the ability of PhIP to induce 
transient end points of breast cell carcinogenesis in MCF10A cells and thus contributed 
towards enhancing its ability to potentiate chronic breast cell carciniogenesis caused by 
co-exposure to TCC and PhIP.  Similar changes were also seen when MCF7 and J82 cells 
were subjected to TCC and PhIP together for a single exposure.  These results indicated 
that TCC was able to augment PhIP-induced constitutive and transient endpoints of breast 
cell carcinogenesis.  Next, in order to evaluate the ability of mimosine and ergosterol to 
suppress breast cell carcinogenesis induced by co-exposure to TCC and PhIP, MCF10A 
cells were co-treated with TCC and PhIP in the absence and presence of non cytotoxic 
concentrations of ergosterol and mimosine in long term exposure for 10 cycles as well as 
short-term exposure for a single cycle.  Results indicated that both mimosine and 
ergosterol inhibited acquisition of cancer-associated properties of anchorage-independent 
growth, reduced dependence on growth factors induced by co-exposure to TCC and PhIP.  
Simultaneous treatment with preventive agents also suppressed chronic increase in cell 
proliferation, ROS production and Erk-Nox activation induced upon co-treatment with 
TCC and PhIP.  Transient endpoints of Erk pathway activation, ROS production, cell 
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proliferation and DNA damage were also suppressed by the two preventive agents.  
These results prove that ergosterol and mimosine were effective in suppressing breast cell 
carcinogensis induced by co-treatment with TCC and PhIP. 
 
To conclude, this study has demonstrated that cumulative exposures of non cancerous 
human breast epithelial cells MCF10A, with physiologically achievable doses of 
triclocarban induced cancer-associated properties of reduced dependence on growth 
factors, anchorage-independent growth in MCF10A cells.  The premalignant breast 
cellular carcinogenesis induced by TCC was characterized by activation of ERK 
pathway, ROS production, DNA damage and increased cellular proliferation.  Curcumin, 
a dietary component of turmeric, easily ingested in the form of curry powder at non 
cytotoxic concentrations inhibited acquisition of cancer-associated properties in MCF10A 
cells and blocked pre-malignant carcinogenesis induced by cumulative exposures to 
TCC.  TCC also enhanced PhIP–induced breast cell carcinogenesis by significantly 
increasing the degree of cancer-associated properties attained by cells treated with PhIP 
alone. Erk pathway activation played a major role in breast cell carcinogenesis induced 
by co-exposure to TCC and PhIP in MCF10A cells.  Ergosterol and mimosine at their 
low nanomolar noncytotoxic concentrations intervened with this TCC and PhIP co-
exposure induced breast cell carcinogenesis in a significant manner.  The mechanism of 
breast cell carcinogenesis and prevention is summarized in the scheme shown in Figure 
4.3.  Exposure to TCC and PhIP induces increased expression of phospho-Erk in a Ras 
independent manner.  Erk activation causes increased expression of downstream Nox-1 
which leads to increase in ROS production.    
  
 
 
Figure 4.3 Schematic summary 
PhIPand its intervention  
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Treatment with these compounds also causes increased ROS production in a Nox-1 
independent manner possibly via mitochondriawhich also contributes towards activation 
of Ras independent Erk pathway.  Finally, ROS production and Erk pathway activation 
causes increased cell proliferation leading to DNA damage and breast cell carcinogenesis.  
Use of preventive agents in the form of curcumin, ergosterol and mimosine intervened 
with Erk pathway activation, ROS production, increased cell proliferation, DNA damage, 
ultimately leading to suppression of breast cell carcinogenesis. 
 
4.2 Future directions 
Our study shows that TCC elevated ROS production in breast epithelial cells and induced 
the ERK pathway in a Ras independent manner.  However, how this portion of ROS was 
induced by TCC in MCF10A and MCF7 cells and how ROS was able to induce Ras-
independent activation of Mek1/2 and Erk1/2 remain to be determined.  We have shown 
the co-exposure of MCF10A cells to TCC and PhIP at physiological concentrations for 
20 cycles can enhance various invitro cancer-associated properties, but this could not 
potentiate tumorigenic potential of PhIP in mice models, therefore it is important to 
identify if further co-treatments with TCC and or treatment with other carcinogens will 
make cells significantly more tumorigenic than P20 cells.  Also, it needs to be determined 
whether TCC can potentite PhIP-induced EMT (epithelial to mesenchymal transition) in 
MCF10A cells.  For example, whether TCC can cause an increase in Aldehyde 
dehydrogenase (ADLH)-positive and mammosphere populations induced by PhIP 
treatment of MCF10A cells and alter other markers of metastasis induced by PhIP 
treatment like causing changes in expression of E-cadherin, Epithelial cell adhesion 
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molecule (EpCAM) , matrix metallo proteinase (MMP)-9, and vimentin.  Also, it needs 
to be studied, whether there are other dietary agents that can intervene with TCC-induced 
or TP-induced breast cellular carcinogenesis.  
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